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 ABSTRACT 
Local infiltration analgesia (LIA) is a new multimodal wound infiltration method. It 
has attracted growing interest in recent years and is widely used all over the world for 
treating postoperative pain after knee and hip arthroplasty. This method is based on 
systematic infiltration of a mixture of ropivacaine, a long acting local anesthetic, 
ketorolac, a cyclooxygenase inhibitor (NSAID), and adrenalin around all structures 
subject to surgical trauma in knee and hip arthroplasty. 
Two patient cohorts of 40 patients scheduled for elective total knee arthroplasty 
(TKA) and 15 patients scheduled for total hip arthroplasty (THA) contributed to the 
work presented in this thesis.  In a randomized trial the efficacy of LIA in TKA with 
regard to pain at rest and upon movement was compared to femoral block. Both 
methods result in a high quality pain relief and similar morphine consumption, but 
fewer patients in the LIA group reported pain of 7/10 on any occasion during the 24 h 
monitoring period (paper I).  
In the same patient cohort the maximal total plasma concentration of ropivacaine was 
below the established toxic threshold for most patients although a few reached 
potentially toxic concentrations of 1.4-1.7 mg/L. The time to maximal detected 
plasma concentration was around 4-6 h after release of tourniquet in TKA (paper II). 
All patients in the THA cohort were subjected to the routine LIA protocol. In these 
patients both the total and unbound plasma concentration of ropivacaine was 
determined. The concentration was below the established toxic threshold. As 
ropivacaine binds to α-1 acid glycoprotein(AAG) we assessed the possibility that 
increased AAG may decrease the unbound concentration of ropivacaine. A40 % 
increase in AAG was detected during the first 24 h after surgery, however the  
fraction of unbound ropivacaine remained the same. There was a trend towards 
increased Cmax of ropivacaine with increasing age and decreasing creatinine 
clearance but the statistical power was too low to draw any conclusion (paper III). 
Administration of 30mg ketorolac according to the LIA protocol both in TKA and 
THA resulted in a similar Cmax as previously reported after 10 mg intramuscular 
ketorolac (paper II, paper IV). Neither age, nor body weight or BMI, nor creatinine 
clearance, correlates to maximal ketorolac plasma concentration or total exposure to 
ketorolac (AUC) (paper IV). 
 
In conclusion, LIA provides good postoperative analgesia which is similar to femoral 
block after total knee arthroplasty. The plasma concentration of ropivacaine seems to 
be below toxic levels in most TKA patients. The unbound plasma concentration of 
ropivcaine in THA seems to be below the toxic level. 
The use of ketorolac in LIA may not be safer than other routes of administration, and 
similar restrictions should be applied in patients at risk of developing side effects. 
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Introduction  
 
Osteoarthritic pain  
In common with other joints, the knee and hip joints are covered with cartilage. The 
touching surfaces are covered with a lubricating synovial membrane that prevents 
friction and pain. Progressive arthritis, trauma, or destructive diseases of the joint 
may lead to cartilage wear and joint damage, resulting in progressively increasing 
pain and stiffness, and decreasing daily function (1).  At a certain point total knee or 
hip replacement may be the only option to regain function and get rid of pain. 
Patients with severe radiographic changes report the best relief of pain upon 
movement after total knee arthroplasty. However, neither radiographic nor 
histological findings seem to predict pain intensity in patients scheduled for total 
knee arthroplasty (2).    
Total knee and hip arthroplasties are considered to be one of the most cost-effective 
interventions available in modern surgery in terms of increased quality-adjusted life 
expectancy (3-5).               
 
Knee and hip arthroplasty 
Total knee arthroplasty (TKA) and total hip arthroplasty (THA) are very common 
procedures at orthopedic clinics in developed countries. These highly successful 
surgical procedures alleviate pain, correct leg deformity and help patients with 
debilitating arthritis to restore function and resume normal activities  (6). During knee 
and hip replacement surgery, damaged bone and cartilage are replaced with 
components made of metal alloys, high molecular-weight polyethylene. In Sweden 
more than12 000 knee arthroplasties (7) and more than  14 000 hip arthroplasties(8) 
are performed every year. This number is expected to increase over the next twenty 
years, because of increasing life expectancy and a high prevalence of osteoarthritis in 
elderly people. 
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Pain after knee and hip arthroplasty 
 
Postoperative pain is common after total joint arthroplasty and effective pain relief 
may be hard to achieve (9,10). Pain compromises the early outcome of knee and hip 
arthroplasty by affecting patient ambulation and compliance with physical therapy. 
Inadequate pain control increases the length of hospital stay, escalates the cost of 
care, and is associated with venous thromboembolism, coronary ischemia, 
myocardial infarction, pneumonia, insomnia, cognitive dysfunction, poor wound-
healing, and slowed overall recovery (11). Further, the experience of severe pain 
during the postoperative period increases the risk of patient demoralization, 
dissatisfaction and chronic pain syndrome (12-15). Thus the aim of pain relief after 
joint replacement surgery is not only to prevent or reduce pain, but also to speed up 
the healing process (16).  
 
Methods of pain relief after knee and hip arthroplasty 
The most effective pain treatment after knee and hip arthroplasty has traditionally 
been opioid analgesics and epidural analgesia (17,18). 
 
Parenteral opioids 
Opioid drugs produce their pharmacological effects, including analgesia, by acting on 
receptors located on neuronal cell membranes. The presynaptic action of opioids to 
inhibit neurotransmitter release is considered to be their major effect in the nervous 
system. Opioids act supraspinally, spinally, and peripherally to produce analgesia, 
thereby reducing sensitization both centrally and peripherally (19,20). 
While opioid analgesic drugs are very effective analgesics for postoperative pain 
management, adequate pain relief is not always achieved. Possible causes may be the 
use of less-than-optimal doses to avoid adverse effects like respiratory depression, 
nausea, vomiting, constipation, urinary retention, excessive somnolence, confusion 
and pruritus (21,22). A previous study at our hospital demonstrated that patient-
controlled analgesia with intravenous morphine either with or without parenteral 
tramadol is insufficient to achieve sufficient pain relief after TKA (23). 
In addition, opioid analgesics are suboptimal for relieving pain, particularly during 
physiotherapy and rehabilitation (24) . 
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Epidural analgesia 
Epidural analgesia may be useful for postoperative pain relief following major lower-
limb joint replacement (25). Common adverse effects of epidural analgesia are 
hypotension, urinary retention, motor block limiting ambulation, and spinal 
hematoma secondary to anticoagulant therapy. The introduction of low-molecular- 
weight heparin for the prevention of postoperative deep-vein thrombosis and 
pulmonary emboli might have increased the risk of spinal hematoma after epidural 
analgesia (26-29). Since similar pain relief may be obtained with methods with a 
lower risk of serious adverse events, a recent review concluded that epidural 
analgesia may no longer be considered the gold standard in this context (30).  
 
Femoral nerve block 
Femoral nerve block is another modality of pain management after TKA that has 
received recognition because of its ability to provide superior analgesia with fewer 
side-effects than intravenous opioids or epidural analgesia (31-37). Femoral block is 
technically demanding, and requires additional anesthetic time (38). Single-injection 
femoral nerve block improves analgesia and reduces postoperative morphine 
requirement (39-41). A disadvantage is the decreased muscle tone of the quadriceps 
muscles, which counteracts effective rehabilitation and increases the risk of patient 
falls (42-45).  In addition, nerve injury (46-50) and local infections (51-53)  have 
been reported. An overall complication rate of 1.5%, and a risk of permanent nerve 
injury of 0.2% have been reported after continuous femoral nerve block with 
indwelling catheter in 1190 patients undergoing knee arthroplasty (54,55). 
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Local infiltration analgesia (LIA) 
The limitations of the previously-mentioned methods of postoperative analgesia 
might have inspired Drs. Kerr and Kohan in Sydney, Australia to develop a 
multimodal wound infiltration technique for control of acute postoperative pain 
following knee and hip replacement surgery (56). Known as local infiltration 
analgesia (LIA), this method is based on systematic infiltration of a mixture of 
ropivacaine, ketorolac and adrenaline around all the structures subjected to surgical 
trauma. In contrast to epidural analgesia and peripheral nerve blocks, multimodal 
infiltration is cheap and requires only limited technical skills.  
LIA reduces postoperative pain at its origin without loss of muscle strength, 
decreases opioid consumption, improves lower-limb function, limits postoperative 
complications, decreases operating room time and shortens hospital stay (5,57-64). 
Some studies have compared LIA after TKA with other methods of postoperative 
pain treatment, such as systemic analgesia and placebo (65-67). However data about 
its efficacy in comparison with other methods with proven analgesic effect, such as 
femoral block (68), was sparse prior to the present project. Information on safety 
margins and the plasma concentration of ropivacaine after LIA was incomplete 
(66,69,70). Regarding ketorolac, no information on plasma concentration after LIA 
was available. 
 
 
Components of the LIA mixture 
The mixture of local infiltration analgesia consists of three components with different 
mechanisms of action: ropivacaine, a local anesthetic, ketorolac a cyclooxygenase 
inhibitor or non-steroidal anti-inflammatory drug (NSAID), and adrenaline.  
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Ropivacaine 
Ropivacaine is a long-acting amide local anesthetic agent of the pipecoloxylidide 
group, structurally related to bupivacaine (71,72) .Compared to bupivacaine, 
ropivacaine is less lipophilic and less likely to penetrate large myelinated motor 
fibers. In isolated animal nerve studies, ropivacaine was more selective for Aδ and C 
(pain) than Aβ (motor) nerve fibers and produced significantly less depression in 
motor fibers as compared to  bupivacaine (73-75) . The mechanism of action of 
ropivacaine, as for all local anesthetics, is the reversible inhibition of Na
+
 channels in 
neurons, blocking the propagation of the action potential along nerve fibers (76) . 
Several other properties of ropivacaine which may be of importance for its use in the 
context of LIA in joint replacement surgery have been described:  
 
Vasoconstriction  
Ropivacaine, at a concentration of 0.2-0.25 %, decreases cutaneous blood flow upon 
direct application in healthy male volunteers (77-80). Similar observations have 
been reported in preclinical animal studies (81). 
 
Anti-inflammatory effects  
Peripheral nerve blocks with ropivacaine after total knee arthroplasty inhibit clinical 
inflammation without detectable changes in cytokine concentrations in tissue and 
plasma (82). In animal studies intravenous ropivacaine exerts anti-inflammatory 
activity by inhibiting both leukocyte rolling and adhesion in ulcerative colitis, and 
decreasing inflammatory mediators in acute lung injury (83,84). Retrospective 
analysis of patients undergoing colon, prostate or breast cancer surgery indicates a 
better long-term outcome after epidural anesthesia/analgesia than after patient-
controlled analgesia (85-87) .  
A recent experimental study suggests that this effect is independent of their known 
role as sodium-channel blockers. Anti-inflammatory properties associated with 
inhibition of tumor necrosis factor have been suggested to be important (88). 
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Antibacterial activity  
Ropivacaine may possess antimicrobial activity. Disruption of microbial cell 
membrane permeability leading to leakage of cellular components and subsequent 
cell lysis has been suggested as the mechanism of action (89). Staphylococcus 
aureus does not multiply in ropivacaine 2 mg/mL at room temperature, and at 37°C 
the colony-forming unit (cfu) is reduced. Incubation in ropivacaine 10 mg/mL for 
six hours killed Staphylococcus aureus  (90). E. coli grows in ropivacaine 2 mg/mL, 
but its cfu is reduced after six hours in 10 mg/mL at 37°C. Ropivacaine 0.1% also 
inhibits the growth of Pseudomonas aeruginosa  (91). 
 
Safety aspects of ropivacaine   
Despite more than a century of use, and substantial achievements in local anesthetic 
development and modifications in clinical practice, systemic toxicity has remained a 
significant and potentially lethal problem (92). Although many anesthesiologists may 
occasionally see mild manifestations of local anesthetic toxicity, serious intoxication 
is rare (93). However, signs of toxicity may be unnoticed in most cases.   
Systemic toxicity of local anesthetics is usually the result of accidental intravasal 
injection or of secondary plasma absorption of a large volume of local anesthetics 
(94-96). Information regarding local anesthetic systemic toxicity (LAST) is based 
mainly on case reports and case series (97). Information regarding the mechanisms of 
LAST is extrapolated from animal studies, since it is unethical to perform human 
randomized controlled trials of local anesthetic toxicity (98).  
 
CNS toxicity 
The central nervous system (CNS) is more sensitive to local anesthetic toxicity than 
the cardiovascular system (76). Unspecific signs of CNS toxicity (dizziness, tinnitus, 
circumoral paresthesia, taste perversion, shivering, muscle twitching and tremors) 
may progress to tonic-clonic seizures due to the blocking of inhibitory cortical 
neurons. With increasing plasma levels, both inhibitory and excitatory pathways are 
blocked, which results in generalized CNS depression with hypoventilation and coma    
(99). Data obtained from healthy volunteers indicates a significantly higher threshold 
for CNS toxicity and less cardiotoxicity with intravenous ropivacaine than with 
bupivacaine (100-102). 
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Cardiovascular toxicity    
Cardiovascular toxicity of local anesthetics is also characterized by a biphasic order 
of events. Initially, tachycardia and hypertension dominate due to an activation of the 
sympathetic nervous system. This phase is followed by direct myocardial depression, 
arrhythmia and prolonged conduction, which may progress to total cardiovascular 
collapse (103). 
 
Mechanisms of local anesthetic cardiac toxicity are still not completely understood. 
The potential cellular sites of local-anesthetic-induced cardiotoxicity include the 
sodium, potassium, and calcium channels, β2-receptors and mitochondrial 
metabolism, and decreased adenosine triphosphate ( ATP) synthesis in the cell 
(102,104-106). Also, Ca
2+
 dysfunction is associated with cardiotoxicity
  
 (92,107-
109).  
 
Mechanisms of cardiac toxicity of local anesthetics 
1. Inhibition of Na+ channels  (110)     
2. Inhibition of K+-channels   (111)   
3. Inhibition of the β2-adrenergic receptor (112)  
4. Dysregulation of Ca2+ release from the sarcoplasmic reticulum (113) 
5. Inhibition of Ca2+ uptake by the sarcoplasmic reticulum(107)  
6. Inhibition of cyclic –adenosine monophosphate production (114)  
7. Inhibition of mitochondrial energy metabolism by decrease in adenosine 
triphosphate ATP (115) 
 
 
Tissue concentrations of local anesthetic drug in the myocardium can be two-to-
three times greater than the concurrent arterial blood concentrations (93) and  
displacement of drugs bound to plasma proteins  occurs in acidosis (116) or in the 
presence of drugs such as β-blockers and calcium-channel antagonists. 
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α-1 acid glycoprotein 
 α-1 acid glycoprotein (AAG) or orosomucoid, an acute-phase protein, is 
synthesized by the liver (117-119). Plasma AAG levels in healthy young adults are 
reportedly in the range of 55-140mg/L (120). Ropivacaine is highly bound (94%) in 
plasma to AAG, and changes in the plasma concentration of this acute-phase 
protein affect the plasma concentration of the unbound fraction of ropivacaine. 
Increased levels of AAG decrease the free concentration and toxicity of ropivacaine 
(121,122). 
A two- to fivefold increase in the plasma concentration of AAG occurs in response to 
various stressful stimuli including physical trauma such as surgery, tissue injury, 
inflammation or infection. After surgery the AAG level increases, peaking  at 3-4 
days postoperatively (118). No information has been presented about the ropivacaine 
plasma concentration after LIA in THA and its relation to AAG.   
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Ketorolac 
Ketorolac is a non-steroidal anti-inflammatory drug (NSAID), which blocks the 
cyclooxygenase (COX) enzymatic pathway and ultimately inhibiting two individual 
prostaglandin pathways (123). The COX-1 pathway is involved in prostaglandin-E2-
mediated gastric mucosal protection and in thromboxane effects on coagulation. The 
inducible COX-2 pathway is involved primarily in the generation of prostaglandins 
included in the modulation of pain and fever, but has no effect on platelet function or 
the coagulation system.  
Both COX-1 and COX-2 may be involved in pain signaling by increasing the 
synthesis of prostaglandin E2 (123,124). COX-1 selective drugs may increase the risk 
of bleeding and COX -2 selective drugs increase the risk of cardiovascular events. 
Intramuscular ketorolac induces pain relief comparable with morphine in a wide 
variety of surgical procedures (125-128).Intra-articular ketorolac produces analgesia 
(129). Decreased prostaglandin E2 concentrations in synovial tissue correlate with 
decreased pain experienced by the patient (130,131). According to a recent study 
ketorolac seems to be  more efficient when given locally in the LIA mixture than via 
the intravenous  route (132) . Compared to LIA without ketorolac, LIA with 
ketorolac reduces morphine consumption and pain intensity (133). Earlier readiness 
for hospital discharge has also been reported (133,134).  
 
Safety of ketorolac  
 
Bleeding 
All COX-1 inhibitors may carry an increased risk of bleeding due to inhibition of 
thromboxane synthesis in platelets. Ketorolac has high selectivity for COX-1. 
However, ketorolac has been administered to patients with intracranial hemorrhage 
requiring craniotomy. These patients had no higher risk of bleeding than controls did 
(135). An increased risk of gastrointestinal bleeding has been reported after the use of 
ketorolac for more than five days (136,137).  
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Cardiovascular risk 
All cyclooxygenase inhibitors/NSAIDS have been linked to increased cardiovascular 
morbidity. The American Food and Drug Administration (FDA) has concluded that 
an increased risk of serious adverse cardiovascular (CV) events may be a class effect 
for NSAIDs (excluding aspirin).  
However, the risk seems to be higher with COX-2 selective inhibitors (138-141). 
COX-2 selective inhibitors block the synthesis of prostacyclin, an endogenous 
antithrombotic prostaglandin (142) and increase the risk of myocardial infarction 
(143). In a meta-analysis of a randomized controlled study of COX-inhibitors, the 
risk of myocardial infarction was higher with COX-2 selective inhibitors than with 
placebo or naproxen (144). Large epidemiological studies in relatively healthy 
individuals  (145),  patients with heart failure (146), and patients with a history of  
myocardial infarction found that the risk of myocardial infarction and death increased 
with COX-2 inhibitors and diclofenac but not with naproxen (145-147). 
Ketorolac has a higher selectivity for COX-1 than naproxen does (148) which may 
indicate a low risk of ischemic cardiovascular events. But data from randomized 
clinical studies is insufficient to prove this hypothesis. However, epidemiological 
studies point towards a lower risk of myocardial infarction with ketorolac than with 
opioids (149).  A recent report on 1300 patients scheduled for cardiac surgery 
concluded that ketorolac carries no increased risk of cardiac events (150). In contrast, 
a recent observational study from Taiwan indicates an increased risk with ketorolac 
(151). 
 
Renal side effects 
All COX-inhibitors/NSAIDS may decrease renal function by inhibiting the synthesis 
of PGE2, which maintains glomerular filtration (152-154). This effect seems to be 
less important in healthy individuals without renal problems (155). However, 
elderly patients or those with hypovolemia, dehydration, cirrhosis, or heart failure 
are more prone to renal impairment by COX-inhibitors (156,157). 
 
Despite the wide use of ketorolac, nephrotoxicity remains a concern (158). 
Numerous case reports have linked ketorolac treatment to renal failure (159-161), 
and even a single dose may induce renal toxicity (162). Ketorolac, as other 
NSAIDs, inhibits  prostaglandin-mediated renal function (159,163) Prostaglandins 
regulate a variety of renal functions such as vascular tone, salt and water balance, 
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and renin release (164). Prostaglandins are synthesized in the kidney, and the 
principal prostaglandins PG E2, -D2  and ,-I2 (prostacyclin) are powerful vasodilators 
(165). This effect does not appear to compromise renal hemodynamics in patients 
with normal renal function.  
The mechanism of renal failure induced by NSAID is the inhibition of  
prostaglandin-induced vasodilatation of the afferent arteriole in conditions of 
reduced renal perfusion, which  reduces glomerular perfusion. In addition, 
concomitant use of angiotensin-converting enzyme inhibitors (ACEI)/angiotensin 
receptor antagonists and  diuretics, especially in  elderly or dehydrated subjects, may 
precipitate acute renal failure, hyponatremia, or hyperkalemia (166-168).  
 
The risk of acute renal failure with parenteral ketorolac has been assessed in a large 
observational study including 10 000 patients (169). The risk with ketorolac 
administered for less than five days was similar to that with opioids. 
However, several case reports of renal failure after ketorolac have been published 
(170-173). At our department we have observed at least two cases of severe renal 
impairment after ketorolac in joint arthroplasty (174) . 
 
Adrenaline 
Adrenaline is a potent agonist at both α- and β-adrenoceptors. It is one of the most 
common additives used to modify the pharmacodynamic and pharmacokinetic 
properties of local anesthetics. Vasoconstriction and less bleeding are the main 
reasons for adding adrenaline to local anesthetics (175,176). 
The addition of adrenaline delays systemic absorption and reduces the peak plasma 
concentration of ropivacaine after thoracic paravertebral block (177,178). Adrenaline  
may have some analgesic effect through α2-agonists, and adrenoceptors can modify 
certain K
+
-channels in the axons of peripheral nerves, potentiating the impulse-
blocking actions of any Na
+ 
-channel inhibitor (i.e. local anesthetics) (179-181).   
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Aims  
 
This PhD thesis presents studies on the efficacy and safety of LIA using ropivacaine 
and ketorolac for post-operative pain management after total knee and hip 
arthroplasty.  
 
 
The aims were to assess 
 
 
1. whether pain relief after LIA in knee arthroplasty is as effective as 
femoral block, 
 
2. whether the plasma concentration of ropivacaine after LIA in knee 
arthroplasty is higher than after femoral block, 
 
3. whether the plasma concentration of ketorolac after LIA in knee 
arthroplasty reaches levels linked to toxicity, 
 
4. whether the maximal dose adjusted concentration of ropivacaine 
after LIA is higher in THA as compared to TKA, 
 
5. whether the plasma concentration of unbound ropivacaine after 
LIA in hip arthroplasty reaches levels linked to toxicity, 
 
6. whether an increase in AAG after hip arthroplasty decreases the 
unbound concentration of ropivacaine, 
 
7. whether the plasma concentration of ketorolac after LIA in hip 
arthroplasty reaches levels linked to toxicity, 
 
8. whether local administration of ketorolac in LIA may be safer as 
compared to the intramuscular route   
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Patients and Methods 
 
All the studies were conducted in accordance with the Declaration of Helsinki and 
according to good clinical practice. They were approved by the Regional Research 
Ethics Committee at the Karolinska Institutet in Stockholm, Sweden and by the 
Swedish Medical Products Agency. Oral and written informed consent was obtained.  
 
 
 
Two patient cohorts were included (table 1):  
 
1) Forty patients with TKA (Papers I, II). 
2) Fifteen patients with THA (Papers III, IV). 
 
Table 1 Patient demographics 
 TKA (n=40) 
Papers I, II 
THA (n=15) 
Papers III, IV# 
Sex (M/F)                                                  19/21                                                 8/7
Age  (mean; range)  68 (29-88 ) 64 (32-85) 
Weight (kg) (mean) 80 88 
BMI (mean) 27 29 
ASA I / II / III 5 /15 /20 4 /4 /7 
TKA= total knee arthroplasty, THA= total hip arthroplasty, M=male, F= female, 
BMI= body mass index, ASA= American Society of Anesthesiologists classification. 
#  In two patients ketorolac was not quantified   
 
Inclusion criteria: patients older than 18 years, American Society of 
Anesthesiologists (ASA) classification I-III, with osteoarthritis or rheumatoid 
arthritis.  
Exclusion criteria: allergy to or intolerance of one of the study drugs, renal 
insufficiency, epilepsy, patients unable to understand the written patient information 
and informed consent form,  mental illness, dementia, QT interval on 
electrocardiogram (ECG) > 450 msec before start.  
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Anesthesia 
All surgical procedures (TKA, THA) were performed under spinal anesthesia at the 
level of L2-L3 or L3-L4 intervertebral space. Isobaric bupivacaine 5 mg/mL at a 
volume of 3 ml was injected with the patient lying with the operating side upwards. 
Before induction of spinal anesthesia, monitoring of oxygen saturation, blood 
pressure and electrocardiogram (ECG) was started. Sedation was induced with 
midazolam 1-2mg IV or propofol 10-30mg IV. 
 
Study Design 
The clinical trial reported in Papers I and II was a prospective randomized open trial.  
The clinical trial reported in Papers III and IV was an open study with no 
comparative treatment.  Both studies were performed at the orthopedic clinic at the 
Karolinska University Hospital in Solna between January 2007 and June 2011.  
This project was not supported by the drug industry.  
 
Total Knee arthroplasty (Paper I, II) 
The patients were assigned at random to one group of 20 patients receiving femoral 
nerve block (F) and one group of 20 receiving LIA. 
 
Group F  
The group F patients received a femoral block with catheter under sterile conditions 
with the patient supine after induction of spinal anesthesia.  
Using the “Winnie approach” (182) and a nerve stimulator connected first to the 
needle and then to the catheter to identify the femoral nerve, ropivacaine 
30mL(2mg/ml) was injected followed by 15 mL of the same concentration every 4 
hours for 24 h (total dose 240mg/24h). In addition this group received IV ketorolac 
10mg eight-hourly for the first 24 h. 
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LIA in Total Knee arthroplasty    
Patients in the LIA group received peri- and intra-articular infiltration of  156 mL 
solution containing150 mL ropivacaine (2mg/mL), 1ml ketorolac  (30mg/mL) and 
5mL adrenaline (0.1mg/mL).This solution was prepared by the operation nurse prior 
to start of the surgical procedure.  
The surgeon infiltrated the LIA solution sequentially:  
1) 30 mL was injected intracutaneously at the start of the operation,  
2) 80 mL was injected into the posterior part of the capsule, close to the incision 
line, in the vastus intermedius and lateralis and around the collateral 
ligaments before cementation,  
3) 46 mL was instilled through an intra-articular catheter (epidural catheter) 
inserted at the end of the surgical procedure.   
 
In the recovery room all patients were provided with a patient-controlled-analgesia 
(PCA) morphine pump programmed to give an intravenous bolus of morphine 2 
mg/dose on demand with a lock-out time of 6 min and maximum dose of 35 mg/4 
hours. All patients were introduced to the PCA technique and encouraged to use it as 
often as needed. After 24 hours PCA pump use was verified with a printout of all 
doses of morphine and their time of administration. 
In addition to PCA all patients received paracetamol (1 g x 4) started in the morning 
of the operation day. All patients were instructed preoperatively by the nurse about 
pain assessment using a numeric rating scale (NRS), no pain = 0, worst imaginable 
pain =10. Pain intensity at rest and upon movement was recorded hourly during the 
first 24 hours by the patient (if awake). ECG was performed preoperatively, two 
hours after the end of surgery in the recovery room and 24 hours postoperatively on 
the ward. 
 
Blood samples in TKA 
Blood sampling for ropivacaine and ketorolac plasma concentration was started 20 
minutes after injecting ropivacaine in the femoral catheter in group F (Time zero “0” 
in the femoral group). In the LIA group the release of the tourniquet was time zero 
“0”.  Additional samples were taken at 40 and 60 minutes and at 2, 4, 6, 12, and 24 
hours. The 12-hour samples were taken only in four patients due to the inconvenient 
sampling time. The blood samples were centrifuged directly, plasma-separated and 
immediately frozen and stored at -20
0
 C until assayed.  
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LIA in Total Hip Arthroplasty  
Fifteen patients undergoing THA received peri-articular infiltration with a mixture of 
100 ml ropivacaine (2 mg/ml), 1 ml ketorolac (30 mg/ml), and 5 ml adrenaline 
(0,5mg). The total volume was 106 ml.  
 
Blood samples in THA  
Blood samples (5ml x 2) for plasma concentration of ropivacaine and ketorolac were 
taken at 10, 20, 30, 45 minutes and 1h, 2h, 3h, 4h, 6h, 8h, 12 h, 24h and 30h after 
completing LIA. The samples were centrifuged directly, plasma-separated, 
immediately frozen and stored at -20
o
 C until assayed. Blood samples for serum 
albumin and creatinine were collected preoperatively. Blood samples for analysis of 
AAG were collected prior to moving the patient to the operating room and 1h, 4h, 
12h and 24 h post-surgery.  
 
Quantification of total and unbound ropivacaine 
Ropivacaine was quantified with liquid chromatography mass spectrometry (LC–
MS) following ultrafiltration and liquid-liquid extraction at the Department of 
Clinical Pharmacology, Karolinska Laboratory, Karolinska University Hospital, 
Huddinge. The limit of quantification was 0.0053 mg/L (20 nmol/L), maximal 
calibration point 2.66 mg/L (10000 nmol/L). Doxepine (Sigma-Aldrich, St. Louis, 
MD) was used as internal standard. The unbound ropivacaine concentration was 
determined following centrifugation of 300 µL plasma at 5500 g for 10 min at 37 
ºC with an angle-head centrifuge using an Amicon ULTRA centrifugal filter (the 
Ultracel-10K membrane contained regenerated cellulose 10000 MWCO, Millipore, 
Billerica, MA).  
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Quantification of AAG 
AAG was analyzed with nephelometry at the Department of Clinical Chemistry at the 
Karolinska Laboratory, Karolinska University Hospital, Solna. The range for 
quantification was 0.35-108 g/L.  
 
Quantification of Ketorolac   
Ketorolac was quantified with liquid chromatography mass spectrometry LC-MS/MS 
using Waters Acquity Ultra-performance liquid chromatograph with a vacuum 
degasser, binary pump, and sample manager connected to a Quattro Premier XE 
tandem mass spectrometer with MassLynx™/Target Lynx™ Software version 4.1 
(Waters Co, Milford, MA, USA). The reference material ketorolac trometamol was 
obtained from USP, Rockville, MD, USA and the internal standard ketobemidon-d4 
was a gift from Professor Ulf Bondesson (Swedish University of Agricultural 
Sciences, Uppsala, Sweden). The quantification limit was 0.01 mg/L for each 
compound and the calibrated range was up to 10 mg/L.  
 
Statistical analysis 
Sample size:  A sample size of 20 in each group has an 80% power to detect a 
difference between means of 1.0 on the NRS with a significance level (alpha) of 0.05 
(two-tailed) using the unpaired Student t- test (paper I).  
A sample of 13-15 patients (papers III and IV) was considered to be sufficient for a 
hypothesis generating study.  
Since we wanted to determine whether the plasma concentration of ropivacaine and 
ketorolac after LIA reached toxic or near-toxic levels, mainly descriptive statistics 
with focus on maximal plasma concentration are presented. The maximal 
concentration of ropivacaine of each patient in the LIA group was compared to that 
of each patient in the femoral block group with an unpaired t test. Graphpad Prizm 
5.02 for Windows www.graphpad.com was used for the statistical analysis and the 
graphs.  P < 0.05 was considered as statistically significant.  
Statistica 12, ( Statsoft Oklahoma, USA) was used to calculate linear correlation and 
estimate the statistical power. A power of at least 80 % was required to draw any 
conclusion on correlation.  
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Specific aims  
 
Paper 1 
Primary aim   
 To assess differences in average pain intensity at rest and upon movement 
during the first 24 hours after TKA in patients with femoral block and LIA. 
   
Secondary aim  
 To determine total morphine use via i.v. PCA pump during the 24 hours after 
TKA in patients with femoral block and LIA.   
 
Ancillary analyses   
 Average pain intensity during 24 hours at rest and upon movement, 
 Average pain following imputation of missing data by “0” if the patient was 
asleep and by last observation carried forward if data was missing for other 
reasons.  
 The fractions of patients who reported pain intensity < 5 at rest and during 
movement, i.e. mild pain intensity (Jensen et al. 2003; 183) in the two study 
groups were compared using Fisher’s exact test. 
 The fractions of patients who reported pain intensity > 7 at rest and during 
movement, i.e. severe pain (Jensen et al. 2003, 183) in the two study groups 
were also compared with Fisher’s exact test. 
 Safety monitoring including indications of cardiac arrhythmias and incidence 
of reported adverse events. 
 
Paper II  
Primary aim  
 To compare the maximal plasma concentration of ropivacaine during the first 
24 hours after LIA and femoral block in TKA. 
 To assess the maximal plasma concentration of ketorolac during the first 24 
hours after LIA in TKA.  
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Paper III 
Primary aim  
 To assess the maximal plasma concentration and the area under the curve 
(AUC) of unbound ropivacaine during 30 hours after LIA in THA. .   
 
Secondary aim  
 To analyze whether patient age, weight, BMI and creatinine clearance 
correlates to the maximal concentration or AUC of unbound ropivacaine after 
LIA in THA.   
 To analyze the contribution of AAG in binding ropivacaine after LIA in 
THA.   
 
 
Paper IV 
Primary aim   
 To document the maximal plasma concentration and the area under the curve 
(AUC) of ketorolac during 30 hours after LIA in THA.   
 
Secondary aim   
 To analyzed whether patient age, weight, BMI and creatinine clearance 
correlates to the maximal concentration or AUC of ketorolac after LIA in 
THA.   
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Results                                                                   
Part 1: Pain     
 
Pain at rest and upon movement after TKA with LIA or with 
femoral block 
 
The average pain intensity during the first postoperative day was low in both groups. 
The average pain intensity at rest (Fig 1) and upon movement (Fig 2) was similar. 
During the first 12 hours at some time points marginally higher average pain intensity 
at rest was detected in the femoral block group as compared to the LIA group. From 
12-24 h the average pain intensity was similar in both groups (Fig 1). With regard to 
pain upon movement from 6 h to 12 hours lightly higher average pain was reported in 
the femoral block group, but from 12-24 h the average pain intensity was slightly 
lower in the femoral block group (Fig 2).  
The average NRS without imputation of missing NRS registration points due to the 
patients being asleep or unable to fill in the CRF due to other activities is presented in 
table 2.  
 
 
 
Table 2. 
Primary Outcome 
 Femoral block  
n = 20 
LIA 
n = 20 
Average pain NRS  
at rest 
2.1 (1.4 – 2.9) 1.6 (1.0 – 2.3)   
Average pain NRS 
upon movement 
2.4 (1.5 – 3.2) 2.4 (1.7 – 3.0) 
Reported data only. Missing NRS registration due to the patients being 
asleep or unable to fill in the CRF due to other activities were not 
imputed. Data expressed as mean (95 % confidence interval).   
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Figure 1. Average pain score (NRS) at rest during 24h after surgery. No data 
recorded for sleeping  patients .  (n=20 in each group)   
 
 
  
Figure 2. Average pain score (NRS) upon movement during 24h after surgery. No 
data recorded for sleeping patients.  (n=20 in each group)  
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     Incidence of “acceptable pain relief” after TKA  
The incidence of NRS < 5, suggested by Jenssen et al. (183) to be indicative of 
acceptable pain relief throughout the 24-hour observation period at rest and on 
movement was twice as high in the LIA group as in the femoral block group 
(Table 3).   
 
 
Incidence of “unacceptable pain relief” after TKA   
The incidence of NRS pain intensity > 7, at rest on one or more occasions during 
the 24 hour observation period was five times higher in the femoral block group 
than in the LIA group (Table 3). NRS > 7 upon movement was reported only by 
1/20 patients in the LIA group as compared to 7/19 patients in the femoral block 
group. This difference was statistically significant (Fisher’s exact test p=0.044).  
 
Table 3 
Ancillary analysis pain intensity after TKA 
 Femoral block (n=19) LIA (n=20) 
NRS < 5 at rest 7/20  12/20  
NRS < 5 upon movement 5/20  8/20  
NRS > 7 at rest 5/20 1/20  
NRS > 7 upon movement    7/20   1/20 
 
                                   
 
NRS< 5 refers to the number of patients who reported pain intensity lower than 5 
throughout the 24 h of observation. NRS>7 refers to the number of patients who reported 
pain intensity greater than 7 once or more often during the 24 h of observation. 
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Morphine use after LIA or femoral block in TKA  
 
The average total morphine use via the i.v. PCA pump during the first postoperative 
day was 10 mg higher in the femoral block group than in the LIA group (Figure 3). 
However, the morphine dose per kg was almost identical in both groups (Table 4).  
 
 
Figure 3.  Average morphine use (PCA) mg for the two groups during the first 24 h 
after surgery. (n=20 in each group) 
 
 
Table 4.  
 Femoral block LIA 
Total morphine (mg)       32 (23 – 41) 24 (16 – 31) 
Total morphine (mg /kg)  0.4 (0.3 – 0.5) 0.3 (0.2 - 0.4) 
Total morphine refers to intravenous morphine administered via a PCA during 24 
hours. Data expressed as mean (95 % CI). 
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Results part 2: Ropivacaine 
 
Ropivacaine concentration after LIA or femoral block in TKA 
The individual pattern of ropivacaine after LIA and during femoral block is shown in 
figure 4 and the maximal detected concentration in figure 5. Maximal plasma 
concentrations in the LIA group were detected at four or six hours after injection. In 
the femoral block group, the highest levels were often detected at 24 hours (Figure 4).  
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Fig 4.  Total plasma concentration of ropivacaine during 24 h. (A) LIA group (n = 20). In 
this group zero “0” refers to release of the tourniquet. The LIA group received 300 mg 
ropivacaine. (B) Femoral block group (n = 19). In this group time zero “0” refers to 
completion of the first injection for femoral block (60 mg), the subsequent doses (30 mg 
every 4 h) are indicated in the figure. 
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Maximal ropivacaine concentration after TKA     
 
Similar maximal plasma concentrations of ropivacaine were detected in the LIA 
group and in the femoral block group during the first 24 hours (Figure 5, Table 5). No 
statistical difference was detected between the LIA group and the femoral block 
group. 
 
 
 
 
Fig 5. Maximal detected concentration of ropivacaine during 24 h. Data expressed as 
maximal concentration for each patient. The line indicates the median. 
 
 
 
Table 5.  
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Ropivacaine concentration after LIA in THA  
 
Ropivacaine was analyzed in all patients, but two blood samples at 10 and 20 minutes 
are missing from one patient. AAG was analyzed in 14 patients. The 24-hour sample 
of one patient is missing. The range of serum albumin was 33-44 g/L.  
Demographic data and plasma concentration for each patient are shown in Table 6.  
The time to maximum unbound plasma concentration was 4-8 h in 12 of 15 patients. 
A 35-year-old patient with normal weight reached the peak unbound concentration 
after 1 hour. A 58-year-old patient with normal weight reached this concentration 
after 2 hours, and a 75-year-old with a BMI of 32 kg/m
2
 did so after 12 hours. 
The maximal detected concentration of total ropivacaine ranged between 0.443 and 
1.356 mg/L.  
 
Table 6  
 
Patient demographics and results for ropivacaine 
 
 
CC: Creatinine clearance was calculated according to Cockroft Gould  
AUC: Area under the curve, M: male, F: female  
 
 
 
 
Patient 
number 
sex 
ASA Age 
years 
Weight 
kg 
BMI 
kg x m2 
CC 
mL/min 
Cmax  
Unbound 
mg/L 
 
Cmax 
Total  
mg/L 
AUC 
unbound 
(0-30h) 
h x mg /L  
Tmax  
Unbound 
hours 
1 M I 65 89 29 82 0.016 0.578 - 4 
2 F I 58 63 24 106 0.013 0.769 0.180 2 
3 M II 54 90 28 134 0.022 0.672 0.317 4 
4 M II 85 75 27 58 0.018 0.995 0.229 4 
5 F I 32 62 24 143 0.015 0.443 0.268 8 
6 F I 35 74 26 150 0.004 0.505 0.075 1 
7 F III 75 100 32 75 0.018 0.872 0.328 12 
8 M III 61 105 36 140 0.023 0.877 0.316 6 
9 M III 79 90 28 62 0.018 1.356 0.290 4 
10 M II 72 83 25 108 0.021 0.754 0.327 4 
11 F III 76 106 40 69 0.026 0.686 0.272 8 
12 F III 71 107 35 98 0.018 0.576 0.313 6 
13 F III 58 106 38 101 0.016 0.548 0.320 6 
14 M III 70 71 24 66 0.031 1.333 0.335 6 
15 M II 65 95 24 159 0.012 0.448 - 4 
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The pharmacokinetic profiles for total and unbound ropivacaine after LIA in THA 
are shown in Fig. 6.  
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Fig. 6. Individual data of unbound (A) and total (B) plasma concentrations of 
ropivacaine versus time during 30 hours after LIA. 
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Ropivacaine concentration after LIA in TKA compared to THA  
 
Division of the median maximal concentration ropivacaine with dose administered 
after TKA and THA reveals that a higher relative concentration was achieved after 
THA. These results seem to support the use of lower doses of ropivacaine in THA 
(200 mg) as compared the TKA (300 mg). The relative maximal ropivacaine 
concentration in THA is 36 % higher as compared to TKA. Table 7   
 
 
 
Table 7 
Comparison of total plasma concentration of ropivacaine after LIA     
 Range (mg/L) Mean (95 % CI)  mg/L 
 
TKA  LIA, n=20 
 
0.435-1.735  0.813 (0.644-0.982) 
Median concentration / dose: 0.758 mg/L / 300 mg   =  0.00253 1/L  
300 mg ropivacaine in TKA 
 
  
THA  LIA, n=15 
 
0.443- 1.356 0.686 (0.602-0.920) 
Median concentration  / dose:    0.686 mg/L / 200 mg   =  0.00343 1/L 
200 mg ropivacaine in THA  
 
  
Relative maximal ropivacaine 
concentration    THA/TKA   
0.00343/0.00253 =  1.36 
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Correlation of Cmax of ropivacaine after LIA in THA  
versus age, creatinine clearance, weight and BMI  
 
A trend towards correlation of Cmax and increasing age and decreasing creatinine 
clearance  was detected (Fig 7).  However, the statistical power of the linear 
correlation of Cmax versus age or creatinine clearance was 53% and 50% respectively. 
Using a two-sided test based on our data at least 29 individuals are needed to get a 
power of 80 % to test the hypotheses that the maximal unbound ropivacaine 
concentration correlates with age and creatinine clearance.  
Neither patient weight nor BMI correlated to the maximal unbound ropivacaine 
concentration (Fig. 7)  
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Fig. 7. Maximum concentration (Cmax) of unbound ropivacaine in relation to  
age (A), creatinine clearance (B), body weight (C)  and BMI (D). 
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Correlation of AUC of ropivacaine and age, creatinine clearance, 
weight and BMI  
 
Neither patient age, nor creatinine clearance,  nor weight nor BMI correlated to the 
AUC of unbound ropivacaine (Fig. 8). 
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Fig. 8. Total exposure of ropivacaine expressed as area under the curve (AUC) in 
correlation to patient age (A), creatinine clearance (B), body weight (C) and BMI 
(D). 
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AAG at different time points after THA  
 
The AAG concentration increased during the first 24 h by a median of 20 percent 
(range 12-37). A small early decrease in AAG was observed within the first four 
hours (Fig. 9).  
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Fig. 9.  Individual plasma concentrations of α-1 acid glycoprotein versus time profile 
(24 h) in 14 patients. Time zero “0” indicates a baseline sample prior to surgery. 
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Correlation of AAG and the percentage of unbound ropivacaine 
after LIA in THA   
 
As illustrated in Fig. 9 the concentration of AAG did not increase during the first 24 
hours after THA. The unbound percentage of total ropivacaine did not correlate to the 
plasma concentration of AAG at 1, 4, 12 or 24 hours (Fig 10).  
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Figure 10.Unbound fraction of ropivacaine expressed as percentage of total at 
different concentrations of AAG (α-1 acid glycoprotein) at 1 h after surgery (open 
circle), at 4 h after surgery (●), at 12 h (▲) and 24 h (*) versus plasma concentration 
during 24 h after LIA in 14 patients. 
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Results part 3: Ketorolac   
 
Ketorolac concentration after LIA in TKA     
 
The individual pattern of the ketorolac plasma concentration is shown in Fig.11  
The range of the maximal plasma concentrations of ketorolac one hour or two hours 
after tourniquet release  in the LIA group was 152-958 ng/ml (95 % percent, 
confidence interval 303-512 ng/ml) (n=19). 
  
 
 
 
Fig. 11.  Total plasma concentration of ketorolac in the LIA group, which received 
30mg ketorolac. In this group zero “0” refers to release of the tourniquet. 
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Ketorolac concentration after LIA in THA 
 
The median of the peak (maximal detected concentration) ketorolac plasma 
concentrations was 0.82 mg/L (range: 0.31-2.16 mg/L). One patient (No 2, table 8) 
had a peak concentration and AUC almost twice as high as the other patients.  
The individual pharmacokinetic profiles for ketorolac during the 30 post-operative 
hours are shown in Fig. 12.  Patient demographics and PK results of ketorolac after 
LIA in THA are presented in table 8  
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Fig. 12. Individual total plasma concentrations of ketorolac expressed as mg/L (left 
Y-axis)  and as ng/ml (right Y-axis) versus time during 30 hours after LIA (n=13).  
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Table 8 
Patient demographics and PK results of ketorolac after LIA in THA 
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Correlation of Cmax of ketorolac after LIA in THA versus age, 
creatinine clearance, weight and BMI  
 
Apart from the outlier described above not even a trend towards a correlation 
between age, creatinine clearance, patient weight or BMI and Cmax could be identified 
(Fig. 13).  
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Fig. 13. Maximum detected concentration (Cmax) of total ketorolac in relation to  
age (A), creatinine clearance (B), body weight (C)  and BMI (D) (n=13). 
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Correlation of AUC of ketorolac after LIA in THA versus age, 
creatinine clearance, weight and BMI  
 
Neither age, nor creatinine clearance, nor patient weight nor BMI displayed any 
correlation to the AUC of ketorolac (Fig 14). 
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Fig. 14. Total exposure  to ketorolac expressed as area under the curve AUC (0-30h) 
correlated to patient age (A), creatinine clearance (B), body weight (C) and BMI (D) 
(n=12). 
 
 
Adverse effects after LIA in TKA and THA with 
ropivacaine and ketorolac  
 
Neither tachycardia, nor arrhythmias on ECG, nor neurological signs of local 
anesthetic toxicity (circum oral paresthesia, tinnitus, muscle twitch or seizure) were 
detected. ECG recording two hours after surgery did not show any prolongation of 
the QT interval >450 msec compared to preoperative ECG in any patient included in 
the present studies on TKA and THA.  
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Discussion  
Pain intensity and morphine consumption after total knee and hip arthroplasty 
with LIA  
 Effective pain relief after knee and hip replacement surgery is crucial not only for 
patient satisfaction but for early mobilization and faster rehabilitation and better 
outcome. Both LIA and femoral block resulted in low average pain intensity during 
the first post-operative day (Paper I). Similar results have been obtained in a recent 
randomized study comparing pain intensity at rest and during movement in 60 
patients with total knee arthroplasty (184).  
However, only 1/20 (5 %) of patients in the LIA group reported pain intensity greater 
than 7/10 on NRS upon movement as compared to 7/19 (37 %) after femoral block.  
No difference between LIA and femoral block was observed with regard to pain at 
rest. These findings are in line with the observation that differences in efficacy 
between treatment modalities may appear only when pain is assessed during function, 
not at rest  (185). Low pain intensity upon movement may be crucial for rapid 
rehabilitation, particularly after joint replacement.  
Femoral nerve block does not cover the posterior part of the knee, which is 
innervated by the sciatic nerve. Some authors recommend a supplementary sciatic 
nerve block to achieve better pain relief after TKA (186,187). However, sciatic nerve 
block may weaken muscles needed for mobilization after surgery (188). 
In addition, femoral nerve block usually produces a partial motor block of the 
quadriceps femoris muscle, which could delay early postoperative mobilization. This 
effect is avoided with LIA (5,24,184).     
With regard to the analgesic efficacy of LIA in total hip arthroplasty (THA) we did 
not compare this to any other method of post-operative pain relief. However, we 
asked all our patients for a general assessment of their satisfaction with the 
postoperative pain management. Eighty-six percent of the patients with THA 
included in studies III/IV, reported good (73 %) or excellent (13 %) pain relief after 
LIA.   
Our data do not permit to draw a conclusion on the exact contribution of  Ketorolac 
to analgesia induced by LIA. However, we have observed less efficient 
postoperative analgesia in patients who received local infiltration analgesia without 
ketorolac in the mixture. In addition, ketorolac is more effective when given intra-
articularly and in LIA compared to other routes of administration (132-134). 
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Ropivacaine plasma concentration after LIA in TKA and THA 
The maximal ropivacaine concentrations observed in knee arthroplasty (Paper II) 
were below the established toxic threshold for most of our patients although two 
individuals reached concentrations of 1.4 – 1.7 µg/mL.  
Similar concentrations have been linked to signs and symptoms of toxicity after i.v. 
administration in healthy volunteers (100,101). In addition, the maximal plasma 
concentration of ropivacaine using the LIA protocol seems to be higher than after 
femoral block during the first 24h. However, studies on peripheral and central block 
have reported even higher plasma concentrations (2 - 4.2 µg/mL) without adverse 
reactions (189,190).   
Very few investigators have studied safety aspects of LIA or assessed plasma 
concentrations of ropivacaine after LIA in TKA and THA. Bianconi et al (70) 
reported total plasma concentrations of ropivacine in patients subjected to elective 
hip/knee arthroplasty. The range of maximum plasma concentration (Cmax) was 
0.30-1.28 µg/mL, which is comparable to our study (Papers II, III).  However, the 
dose used in that study was 200 mg ropivacaine plus a continuous infusion of 10 
mg/h for 55h. The maximal concentration was detected 24h after LIA. Vendittoli et 
al (66) reported a plasma concentration of ropivacaine in the range of 0.65-1.35 
µg/mL after LIA with 275 mg. However, the plasma concentration was monitored 
during 90 minutes only and a higher plasma concentration later than 90 minute 
could not be detected.   
The maximal detected concentration of ropivacaine in our studies was reached 
around four to six hours after LIA. By that time most of the patients had been 
moved from the post-anesthetic recovery room to the ward and minor signs and 
symptom of toxicity may have passed unnoticed.  
 
To avoid plasma levels higher than those after a single dose, a reduced bolus dose 
may be considered prior to removal of the peri-articular catheter at 24 h. 
 
Since only the unbound fraction of ropivacaine is pharmacologically active, we 
assessed both unbound and total plasma concentration of ropivacaine after LIA in 
THA (paper III). The range of the maximal detected unbound plasma concentration  
during 30 hours after LIA with 200 mg ropivacaine was 0.004 – 0.03 µg/mL. The 
upper limit of this range is close to the maximal unbound levels of ropivacaine (0.038 
µg/mL) reported after the same dose of ropivacaine (200 mg) in LIA without 
 55 
 
epinephrine (191). During four hours after LIA with 400 mg ropivacaine in THA, a 
maximal concentration of unbound ropivacaine of 0.06 µg/mL was reported in five 
patients (192) .The same dose of ropivacaine in LIA for TKA resulted in a maximal 
unbound concentration of 0.032-0.12 µg/mL in 8 patients (193). 
Our results indicate that higher age and lower creatinine clearance may correlate to 
the maximal unbound ropivacaine concentration. However, a statistical power of 66 
% for age and 50 % for creatinine clearance was insufficient. At least 29 individuals 
are needed to test these hypotheses with 80 % power based on our patient cohort 
without severe renal impairment. In our cohort, neither creatinine clearance, nor age, 
nor body weight correlated with the AUC of unbound ropivacaine. Renal function 
may be of greater importance for the AUC during continuous infusion than after a 
single infiltration as used in our protocol. 
 
 
Safety aspects of ropivacaine 
Knowledge of the potential risks of cardiac or central-nervous-system side-effects at 
different concentrations of ropivacaine is based on data obtained from early studies 
with healthy volunteers who received intravenous infusion of ropivacaine (101).  
Side-effects sufficient to stop the intravenous infusion were reported at arterial 
concentrations of 0.34-0.85 µg/mL. This range has been considered to represent a 
relevant safety limit or neurological toxicity range for venous plasma concentration 
of unbound ropivacaine (194). However, the clinical relevance of this range may be 
questioned. Considerably higher unbound concentrations without adverse reactions 
have been reported during epidural or local infusion (195-197). 
We did not detect any signs or symptoms of ropivacaine toxicity after LIA in the 
patients included in the present studies. A potential risk of local anesthetic toxicity 
during arthroscopic knee surgery is illustrated by case reports of healthy patients 
subjected  to synovial surgery with local administration of bupivacaine (75 mg and 
150 mg) (198,199). 
Regarding the effect of tourniquet use, a previous study suggests that a longer 
duration of tourniquet ischemia may lead to a faster absorption of local anesthetics 
and higher peak plasma level due to enhanced post-ischemic reperfusion. In contrast, 
the longer duration of tourniquet inflation after local anesthetics injection increases 
tissue binding, and decreases peak serum levels (200). 
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Regarding THA, the tourniquet does not apply but the surgical wound is large and the 
possibility of absorption of local anesthetics is greater. A lower dose of ropivacaine 
(200 mg instead of 300 mg) may decrease the risk of high plasma concentration. The 
maximal total concentration after LIA with 300 mg in TKA was 0.81µg/mL, and 
after LIA with 200 mg in THA was 0.78µg/mL. Thus, the absorption of ropivacaine 
is greater after LIA in THA than in TKA. 
 
Ropivacaine binding to α-1 acid glycoprotein (AAG)  
Ropivacaine binds mainly to AAG (201,202).  This protein increases in stress 
conditions like surgical trauma. We detected AAG levels similar to those in young 
healthy adults (120). After 24 hours the AAG level in our study had increased by less 
than 40 percent, which did not result in any significant change in the unbound 
concentration of ropivacaine. AAG increases after 24 hours, as shown in several 
studies of prolonged infusion of ropivacaine (195,203,204).  AAG levels may double 
around 4 days postoperatively and seem to reach a maximal concentration at the sixth 
to twelfth postoperative day (205,206). 
 
Ketorolac  
Information on ketorolac plasma concentration after LIA in knee or hip arthroplasty 
has not been presented yet (March 2014). In paper II the range of the maximal 
detected plasma concentration of ketorolac after LIA in knee arthroplasty was 0.15 
– 0.96 mg/L. In hip arthroplasty (paper IV) the maximum plasma concentration of 
ketorolac after LIA was 0.82 mg/L (0.31-2.16). This is comparable to the maximal 
plasma concentrations after 10 mg ketorolac given intramuscularly in healthy 
volunteers 0.77 mg/L (207).  
We could not find any correlation between peak concentration or Cmax and the patient 
age within our cohort. These results are line with the reported similar range after an 
intramuscular injection of 30 mg ketorolac in young adults (mean age 30 years) and 
healthy elderly (mean age 72 years) (207).  
We could not demonstrate any effect of creatinine clearance on the peak 
concentration of ketorolac within the range present in our cohort 58-150 ml/min. 
Renal function is more important for total exposure or AUC than the peak 
concentration after a single dose. However, we could not find any correlation 
between creatinine clearance and AUC either. A tendency towards higher AUC after 
intramuscular injection of 30 mg ketorolac to elderly as compared to younger adults 
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has been reported (207).  We could presume that individuals with creatinine 
clearance lower than 50 ml/min may have higher AUC. But due to safety concern of 
ketorolac in patients with reduced renal function a clinical trial on this issue may be 
ethically questionable.       
Our data on ketorolac after LIA do not seem to help identify patients with a higher 
risk of potential adverse events. Instead it seems reasonable to avoid ketorolac in 
patients with congestive heart failure treated with ACE inhibitors or ARB and in 
patients with low creatinine clearance. The optimal cutoff level of creatinine 
clearance remains to be established.   
 
 
Adrenaline  
 
The dose of adrenaline in LIA is 0.5 mg. Its presence in the LIA mixture may be 
advantageous as a cardiovascular marker to detect intravascular injection.  
However, the optimal dose of epinephrine in the LIA mixture based on a risk / 
benefit analysis has not been established. Adrenaline increases pulse and blood 
pressure and exposes the patient to an increased risk of cardiac ischemia. So far the 
benefit of adrenaline in the LIA protocol seems to be based on tradition and 
assumptions rather than solid scientific evidence.  
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General discussion 
 
Systemic toxicity from local anesthetics is relatively rare. However, local anesthetic 
toxicity can be catastrophic to the individual when it does occur. 
Although many anesthesiologists may occasionally see mild manifestations, most 
never encounter serious intoxication.  
In most of our patients the plasma concentration of ropivacaine after LIA in knee and 
hip arthroplasty did not reach levels linked to toxicity. However, patients undergoing 
knee and hip arthroplasty are usually old with various medical diseases. Slow 
incremental and frequent aspiration during LIA mixture infiltration is advisable.  
Lipid emulsion should be available for use in case of toxicity, since this therapy is 
effective for treating local anesthetic toxicity (208). However, the mechanism of the 
reversal of toxic effects of local anesthetics by lipid emulsion is still unclear. One 
theory is that it creates a lipid plasma phase that essentially extracts the high lipid-
soluble local anesthetic molecules from the aqueous plasma phase (209-211). 
An important question still not answered is how much local anesthetic is required in 
the LIA mixture to produce the optimal therapeutic effect.   
The manufacturer Astra Zeneca recommends a maximal dose of 225mg.  Higher 
doses of ropivacaine are used in various institutions both in knee and hip arthroplasty. 
It may be difficult to recommend a safe maximal dose of local anesthetics because 
individuals vary in their sensitivity to local anesthetics toxicity, as has already been 
observed in a ropivacaine toxicity study in healthy volunteers (101). The correlation 
between blood levels and signs of toxicity is considered multifactorial as 
physiological, anatomical and pharmacokinetic factors all contribute (212). 
Although we could not find any previously reported case of ropivacaine toxicity after 
LIA in knee and hip arthroplasty, this does not mean that the possibility of its 
occurrence is negligible, especially in severely ill patients with renal and hepatic 
impairment.   
It seems that single doses may carry a lower risk of toxicity than continued infusion; 
but scientific proof for this assumption is at least weak.  
 
Older patients may have a higher peak of unbound ropivacaine than younger ones. 
We found a trend towards a correlation between age and unbound maximal 
ropivacaine, at least 29 individuals are needed to get sufficient power based on our 
data. It may be advisable to use lower doses of ropivacaine in patients at higher risk 
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of developing adverse events. However, our data are insufficient to provide an exact 
dose recommendation for these patients.  
Intuitively, the ”one size fits all” approach using the same dose of ropivacaine for a 
patient weighing a hundred kilos and one weighing fifty may seem inappropriate. 
However, our data do not indicate that dosage-per-kilo carries a lower risk of peak 
concentrations of ropivacaine.  
 
Ketorolac plasma concentration after LIA infiltration in both knee and hip  
arthroplasty  is not negligible, and the risk of renal side-effects should be kept in 
mind. Age 80 years or older is an independent risk factor for NSAID 
nephrotoxicity, since 50% of 80-year-old patients have already lost half their 
glomerular filtration rate (31).  Patients with congestive heart failure, hepatic 
cirrhosis, hypovolemia or underlying renal disease are more susceptible to 
ketorolac-induced nephrotoxicity (213,214). Heart failure is increasingly diagnosed 
in the elderly and 30–50% of these patients with heart failure suffer from some 
degree of renal insufficiency, making their kidneys even more vulnerable to renal 
adverse events. 
Increasing life expectancy, with a growing geriatric population, produces a new 
cohort of elderly surgical candidates extremely vulnerable to potential nephrotoxic 
effects of combinations of drugs, in particular in clinical conditions where renal 
perfusion is reduced.  
In our department we had two cases of renal failure after hip and knee arthroplasty 
after local infiltration analgesia with ketorolac. Both patients were elderly (80 and 
89 years) with concomitant treatment with ACE inhibitors or ARB. One required 
renal dialysis treatment (174). 
Based on these observations we now avoid ketorolac in LIA in patients with renal 
impairment treated with ACE inhibitors or ARB. 
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Conclusion 
 
1. Pain relief after LIA in knee arthroplasty is as effective as femoral 
block. 
 
 
2. The plasma concentration of ropivacaine after LIA in knee 
arthroplasty is slightly higher than after femoral block. 
 
 
3. The plasma concentration of ketorolac after LIA in knee 
arthroplasty does not reach levels linked to toxicity. 
 
4. The maximal dose adjusted concentration of ropivacaine after LIA 
may be 36 % higher in THA as compared to TKA. 
 
5. The plasma concentration of unbound ropivacaine after LIA in hip 
arthroplasty does not reach levels linked to toxicity. 
 
6. An increase in AAG by 40 percent after 24 hours has no effect on 
the unbound concentration of ropivacaine after hip arthroplasty. 
 
7. The plasma concentration of ketorolac after LIA in hip 
arthroplasty did not reach levels linked to toxicity.  
 
8. The same safety considerations as for intravenous or 
intramuscular ketorolac should be applied for ketorolac in LIA.  
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In 1943, the first amino-amide local anesthetic was developed in Sweden by Löfgren 
and Lundquist, and this xylidine derivative, which they called lidocaine, was first 
marketed in 1948. Lidocaine has been in clinical use for more than 60 years. It is the 
most widely used local anesthetic worldwide and remains one of the safest and most 
efficacious local anesthetic agents ever manufactured (Lofgren NL. Studies on local 
anesthetics: II Svensk Kem Tidskr 1946; 58: 206-17). 
It is worth mentioning that xylocaine was introduced for the first time clinically at the 
Karolinska Hospital, in 1944, by Professor Torsten Gordh. Professor Gordh was the 
first anesthetist in our department and in Sweden. 
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Background and purpose   Pain after total knee arthroplasty 
(TKA) is usually severe, and epidural analgesia or femoral nerve 
block has been considered to be an effective pain treatment. 
Recently, local infiltration analgesia (LIA) has become increas-
ingly popular but the outcome of this method regarding the anal-
gesic effect has not been fully evaluated. We compared local infil-
tration analgesia and femoral block with regard to analgesia and 
morphine demand during the first 24 h after TKA.
Methods   40 patients undergoing TKA under spinal anesthe-
sia were randomized to receive femoral nerve block (group F) or 
peri- and intraarticular infiltration analgesia (group LIA) with a 
mixture containing ropivacaine, ketorolac, and epinephrine. All 
patients had access to intravenous patient-controlled analgesia 
(PCA) with morphine postoperatively. Pain intensity at rest and 
upon movement was assessed on a numeric rating scale (0–10) on 
an hourly basis over 24 h if the patients were awake. 
Results   The average pain at rest was marginally lower with 
LIA (1.6) than with femoral block (2.2). Total morphine consump-
tion per kg was similar between the 2 groups. Ancillary analysis 
revealed that 1 of 20 patients in the LIA group reported a pain 
intensity of > 7 upon movement, as compared to 7 out of 19 in the 
femoral block group (p = 0.04). 
Interpretation   Both LIA and femoral block provide good anal-
gesia after TKA. LIA may be considered to be superior to femoral 
block since it is cheaper and easier to perform.
 
Pain after total knee arthroplasty (TKA) is usually severe and 
difficult to manage, and insufficient pain relief may delay 
recovery. The most effective pain treatment has traditionally 
been epidural analgesia or femoral nerve block (Singelyn et 
al. 1998, Ganapathy et al. 1999, Chelly et al. 2001, Davies et 
al. 2004, Ilfeld et al. 2006) in combination �ith opioid anal�
gesics and non�steroidal anti�inflammatory drugs (NSAIDs, 
cyclooxygenase (cox) inhibitors). Each of these methods has 
its specific side effects. Urinary retention and muscular �eak�
ness are often reported after epidural analgesia. Unpleasant 
numbness of a large part of the lo�er extremity is common 
after femoral block. Opioid analgesics often cause sedation, 
nausea and vomiting, and also urinary retention. Non�selective 
cox inhibitors may cause gastrointestinal bleeding, renal com�
plications, and epidural hematoma, especially in combination 
�ith anti�thrombotic prophylaxis �ith lo��molecular��eight 
heparin (Afzal et al. 2006). 
An alternative method for postoperative pain relief after 
TKA, �hich has attracted gro�ing interest in recent years, is 
multimodal �ound infiltration analgesic technique consisting 
of peri� and intraarticular infiltration of local anesthetics and 
NSAID in the knee (LIA) (Andersen et al. 2008a, b,  Kerr and 
Kohan 2008). This technique appears to offer several advan�
tages over traditional methods, since the analgesia affects 
only the surgical area �ith limited interference of the muscle 
strength. Thus, easier rehabilitation of the operated extremity 
and earlier discharge from the hospital can be expected (Reilly 
et al. 2005, Essving et al. 2009). Furthermore, recent studies 
have sho�n that the LIA technique reduces the requirement 
for postoperative analgesia �ith opioids (Tanaka et al. 2001, 
Busch et al. 2006, Vendittoli et al. 2006). 
Only a fe� investigators have randomly compared LIA �ith 
other methods �ith proven analgesic effect, such as femoral 
block or epidural analgesia (Parvataneni et al. 2007, Toftdahl 
et al 2007). Parvatanemi and collaborators (2007) have sho�n 
that a combination of a femoral block and local administra�
tion of bupivacaine, morphine, and epinephrine results in 
better pain relief and patient satisfaction than femoral block. 
Toftdahl and collaborators (2007) presented data suggesting 
that LIA �ith ropivacaine, ketorolac, and epinephrine results 
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in faster postoperative activation, as indicated by being better 
able to �alk more than 3 m on the first postoperative day 
as compared to femoral block. A retrospective comparison 
(DeWeese et al. 2001) indicated that epidural anesthesia �ith 
fentanyl and bupivacaine resulted in better pain relief and less 
use of other analgesics than did continuous infiltration of the 
knee �ith bupivacaine.
Femoral block is kno�n to be an effective pain treatment 
after TKA (Szczuko�ski et al. 2004, Navas et al. 2005, Duarte 
et al. 2006). We compared the LIA technique �ith femoral 
block regarding efficacy of pain management at rest and upon 
movement after TKA. We also investigated �hether LIA 
reduced the demand for intravenous morphine, administered 
via a patient�controlled analgesia (PCA) pump during the first 
24 h postoperatively. 
Patients 
This randomized parallel clinical 1:1 trial �as used to com�
pare t�o protocols of postoperative pain relief after total knee 
arthroplasty. The inclusion criteria �ere as follo�s: patients 
�ith osteoarthritis or rheumatoid arthritis scheduled for pri�
mary unilateral elective total knee arthroplasty under spinal 
anesthesia, American Society of Anaesthesiologists (ASA) 
classification I–III, and more than 18 years old. Exclusion cri�
teria �ere allergy or intolerance to one of the study drugs, 
renal insufficiency, epilepsy, language difficulty, mental ill�
ness, dementia, QT interval on ECG > 450 msec before start. 
After giving oral and �ritten informed consent, 40 patients 
scheduled for primary unilateral total knee arthroplasty �ere 
randomly assigned to 2 groups of postoperative pain manage�
ment immediately before the surgical procedure.
The setting of this single�site academic trial �as the ortho�
pedics clinic at Karolinska University Hospital in Solna. The 
first patient �as included on January 15, 2007 and the final 
patient �as included on March 25, 2008. 
Randomization 
The randomization sequence �as determined by mixing 40 
tickets, 20 labeled “F” and 20 labeled “LIA” in sealed opaque 
envelopes, and dra�ing one envelope at a time. The anesthesi�
ologist performing the spinal anesthesia and femoral block or 
supervising the LIA technique did not participate in the rand�
omization procedure. 
Interventions
Group F received a femoral block �ith ropivacaine (Narop; 
Astra Zeneca) and group LIA received peri� and intraarticular 
infiltration �ith ropivacaine + ketorolac (Toradol; Roche) and 
epinephrine (Adrenalin; NM Pharma).
Preparation
Before induction of spinal anesthesia, monitoring of oxygen 
saturation, blood pressure, and electrocardiogram (ECG) �as 
started. Sedation �as induced �ith midazolam (Midazolam; 
Alpharma), 1–2 mg intravenously. The level of spinal anes�
thesia �as L2�L3 or L3�L4. Isobaric bupivacaine (Marcain 
Spinal; Astra Zeneca), 5 mg/mL at a volume of 3 mL, �as 
injected �ith the patient lying �ith the operating side up�ards. 
Before the start of the operation, all patients �ere sedated 
�ith midazolam or propofol (Propofol; Abbot), maintaining 
spontaneous ventilation. All patients received 2 g dicloxacil�
lin intravenously before surgery. Antithrombotic therapy �ith 
lo��molecular��eight heparin (LMWH), enoxaparinnatrium 
(Klexane; Aventis Pharma) 40 mg, started the day before sur�
gery and �as given for at least 5 days. The TKA procedure 
�as performed follo�ing application of a thigh tourniquet, 
�hich �as inflated just before skin incision and released after 
�ound closure.
Group F
These patients received a femoral nerve block directly after 
spinal anesthesia. They �ere placed in the supine position. 
Under sterile conditions, the pulse of the femoral artery �as 
identified, the needle (Plexolong Nanolin cannula facette 19G 
× 50 mm; Pajunk) connected to a nerve stimulator (Simplex B, 
serial no 17002; Braun) set up to deliver 1.2 mA �as inserted 
cephalad, 45 degrees to skin and at the level of femoral crease, 
1–1.5 cm lateral to the femoral artery pulse (Winnie et al. 
1973). The femoral nerve �as identifi ed by eliciting quad�
riceps muscle contractions (“dancing patella”). The current 
�as gradually reduced to achieve t�itches of the quadriceps 
muscle at 0.2–0.4 mA and the catheter (StimuLong Sono; 
Pajunk) �as advanced through the needle.
The connection of the nerve stimulator �as changed from 
needle to catheter, and stimulation intensity �as started at 1.2 
mA until the desired motor response �as obtained. There�
after, the intensity �as reduced to 0.2–0.4 mA. The catheter 
�as secured in place �ith transparent dressing. After negative 
blood aspiration, 30 mL ropivacaine (2 mg/mL) �as injected 
follo�ed by 15 mL of the same concentration every 4 hours 
for 24 h (total dose 240 mg/24 h). All patients had a urinary 
bladder catheter, inserted after spinal anesthesia and removed 
on the day after surgery. Group F received ketorolac (10 mg 
intravenously) in the post�anesthetic care unit, and again after 
8 h and 16 h. The total dose of ketorolac �as 30 mg. 
Group LIA
These patients received peri� and intraarticular infiltration of 
a solution containing 150 mL ropivacaine (2 mg/mL), 1 ml 
ketorolac (30 mg/mL), and 5 ml epinephrine (0.1 mg/mL). 
This solution �as prepared by the operation nurse before 
the start of the surgical procedure. The solution �as given 
sequentially: 30 mL �as injected intracutaneously at the start 
of the operation, 80 mL �as injected into the posterior part of 
the capsule, close to the incision line, in the vastus interme�
dius and lateralis and around the collateral ligaments before 
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cementation, and 46 mL �as instilled through an intraarticular 
catheter (epidural catheter gauge 16) inserted at the end of the 
surgical procedure. The total dose of ropivacaine during the 
first 24 h postoperatively �as 300 mg and the total dose of 
ketorolac �as 30 mg. 
Recovery
In the recovery room, all patients �ere provided �ith a patient�
controlled analgesia (PCA) morphine pump (Abott Pain Man�
ager; Abbot Laboratories) programmed to give an intravenous 
bolus of morphine (2 mg/dose) on demand �ith a lock�out 
time of 6 min and maximum dose of 35 mg over 4 h. All 
patients �ere introduced to the PCA technique and encour�
aged to use it as often as needed. After 24 hours, PCA pump 
use �as verified �ith a printout of all doses of morphine and 
their time of administration. In addition to PCA, all patients 
received paracetamol (1 g × 4), either orally or intravenously. 
All patients �ere informed preoperatively by the nurse 
about pain assessment using a numeric rating scale (NRS): 0 = 
no pain and 10 = �orst imaginable pain, based on the visual 
analog scale. NRS score at rest or upon movement during the 
first 24 h �as recorded on an hourly basis by the patients, if 
a�ake.
ECG �as performed preoperatively, 2 h after the end of 
surgery in the recovery room and 24 h postoperatively in 
the �ard. All patients received postoperative physiotherapy, 
�hich started on the morning after operation. 
Statistics
Po�er analysis �as performed using average VAS/NRS score 
during 24 h as the primary variable. A previous study of 
patients undergoing knee arthroplasty treated �ith a femoral 
nerve block reported a mean visual analog scale score of 3.6 
(SD 1.1) upon movement, at 24 h (Singelyn et al. 1998). We 
�anted to be able to detect a difference of 1 unit bet�een LIA 
and femoral block. A sample size of 20 in each group �ould 
have 80% po�er to detect a difference bet�een means of 1.0 
�ith a significance level (alpha) of 0.05 (t�o�tailed) using the 
unpaired Student’s t�test (GraphPad StatMate 1.0; GraphPad, 
San Diego, CA).
Outcomes 
Primary outcome. Differences in average pain intensity at rest 
and upon movement during the first 24 h after TKA �ere ana�
lyzed �ith the Mann�Whitney U�test. As �e had 2 primary 
efficacy outcomes, a significance level of p < 0.02 �as chosen 
for each analysis. No data �ere imputed for the primary out�
come if the patient �as asleep or unable to record NRS. 
Secondary outcome. Total morphine use via the intravenous 
PCA pump during the 24�h period in the 2 study arms �ere 
analyzed �ith the Mann�Whitney U�test. Descriptive statistics 
�ere used to describe the morphine dose per kg in each study 
arm. 
Ancillary analyses
These �ere as follo�s. 1. Average pain intensity in 24 hours 
follo�ing imputation of missing data. Missing data �as 
replaced by “0” if the patient �as asleep. The most recent 
NRS score obtained �as used to replace missing if pain rating 
�as not provided due to other reasons. 2. The fraction of 
patients �ho reported a degree of pain intensity of < 5 at rest 
and during movement, i.e. mild pain intensity (Jensen et al. 
2003) in the 2 study groups �as compared �ith Fisher’s exact 
test. 3. The fraction of patients �ho reported a pain intensity 
of > 7 at rest and during movement, i.e. severe pain (Jensen et 
al. 2003) in the t�o study groups �as compared �ith Fisher’s 
exact test.
Safety monitoring
We monitored indications of cardiac arrhythmias and inci�
dence of reported adverse events.
Ethics
This trial (protocol no. 4773 KCR S2006�011) �as conducted 
according to the Helsinki declaration and �as approved by the 
regional ethics committee of the Karolinska Institute (EPN 
151:2006/34610) and the S�edish Medical Product Agency 
(EudraCT 2006�002581�19). The trial �as monitored by the 
Karolinska Trial Alliance. This trial �as not registered in the 
FDA database of clinical trials.
Results
40 patients participated in this trial, �hich �as conducted. 
20 patients �ere randomized to LIA and 20 to femoral block. 
All patients completed the study. Data �ere analyzed accord�
ing to strict intention�to�treat (sITT) analysis according to 
Herman et al. (2009). One patient in the F group had a his�
tory of insensitivity to pain. He did not demand any morphine 
by PCA and pain �as assessed as 0 on the NRS at all time 
points. The most recent NRS score obtained �as used to 
replace missing if pain rating �as not provided due to other 
reasons The most recent NRS score obtained �as used to 
replace missing if pain rating �as not provided due to other 
reasons and there �as no use of morphine by PCA and 0 on 
the NRS at all times. This rare condition �as not detected 
by the screening physician at inclusion in the trial. Exclusion 
of the data obtained from this patient and analysis accord�
ing to modified intention�to�treat method (mITT) (Herman et 
al. 2009) did not affect the outcome data (data not sho�n). 
The baseline characteristics and the demographic data of the 
patients �ere similar in both groups—except for the average 
�eight, �hich �as higher in the femoral block group (Table 
1). On average, 6 hourly time points of 24 �ere missing due 
to the patients being asleep or unable to fill in the CRF due to 
activities outside the �ard. 
444 Acta Orthopaedica 2011; 82 (3): 441–447
Primary outcome
The average degree of pain intensity during the first postop�
erative day �as lo� in both groups. The average degree of 
pain intensity at rest and upon movement �as similar (Table 
2 and Figure 1).
Secondary outcomes
The average total morphine use via the intravenous PCA pump 
during the first postoperative day �as 10 mg higher in the fem�
oral block group than in the LIA group, but this difference �as 
not statistically significant (Figure 2). Ho�ever, the morphine 
dose per kg �as almost identical in both groups (Table 3). 
Ancillary analysis
1. Imputation of missing data by “0” if the patients �as asleep, 
and using the most recent NRS score to replae missing data if 
pain rating �as not provided due to other reasons resulted in a 
mean NRS at rest of 2.2 (95% CI: 1.4–3.1) in the femoral block 
group and of 1.5 (CI: 0.8–2.1) in the LIA group. The average 
pain score upon movement, follo�ing imputation of missing 
observations, �as 2.2 (CI: 1.5–3.0) in the femoral block group 
and 2.1 (CI: 1.5–2.8) in the LIA group. 2. Incidence of NRS 
less than 5 throughout the 24�h observation period (probably 
acceptable pain relief) at rest and upon movement �as t�ice 
as high in the LIA group than in the femoral block group 
(Table 4). 3. The incidence of NRS pain intensity greater than 
7 at rest on one or more occasions during the 24�h observation 
period �as 5 times higher in the femoral block group than in 
the LIA group (Table 4). NRS greater than 7 upon movement 
�as only reported by 1 of 20 patients in the LIA group and 7 
of 19 patients in the femoral block group (p = 0.04, Fisher’s 
exact test).
Safety analysis 
None of the patients had prolonged QT interval at the ECG 2 
hours and 24 hours postoperatively. No adverse events �ere 
reported during the 24�h study period. 
Table 1. Baseline patient demographics
  Femoral block LIA
Sex (M/F)        8 / 12        11 / 9
Age, mean (range)       69 (53–88)       67 (29–85)
Weight in kg, mean (SD)  83 (13) 78 (18)
Length in cm, mean (SD) 168 (9) 171 (11)
BMI (mean) 27 27
ASA I / II / III 2 / 8 / 10 3 / 7 / 10
RA / OA 3 / 17 6 / 14
M: male; F: female; RA: rheumatoid arthritis; OA: osteoarthritis; 
ASA: American Society of Anaesthesiologists classification. 
Table 2. Primary outcome
 Femoral block  LIA
 n = 20 n = 20
Average pain NRS at rest a 2.1 (1.4–2.9) 1.6 (1.0–2.3) 
Average pain NRS upon movement a 2.4 (1.5–3.2) 2.4 (1.7–3.0)
a Reported data only. Missing NRS registrations due to the patients 
being asleep or unable to fill in the CRF due to other activities were 
not imputed. Data are expressed as mean (95% CI). 
Figure 1. Average pain score (NRS) at rest and upon movement over 24 h after surgery. If the 
patient was sleeping, no data were recorded (n = 20 in each group). 
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Figure 2. Average morphine use (PCA) in 
mg for the 2 groups during the first 24 h 
after surgery (n = 20 in each group). 
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Table 3. Secondary outcome
 Femoral block LIA
Total morphine (mg)  32 (23–41) 24 (16–31)
Total morphine (mg/kg)  0.4 (0.3–0.5) 0.3 (0.2–0.4)
Total morphine refers to intravenous morphine administered via a 
PCA in 24 h. Data are expressed as mean (95% CI).
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Discussion 
Our data indicate that the 2 analgesic regimens gave similar 
quality of pain relief during the first 24 h. Some studies have 
compared LIA �ith other pain treatments after TKA, such 
as systemic analgesia and placebo, and have reported supe�
rior outcome �ith LIA regarding postoperative analgesia and 
opioid consumption. The positive results in those studies are 
not surprising, since the analgesic treatment in the control 
groups mainly consisted of less effective methods of post�
operative pain treatment (Lombardi et al. 2004, Vendittoli et 
al. 2006, Parvataneni et al. 2007, Rostlund and Kehlet 2007, 
Andersen et al. 2008, Kerr and Kohan 2008, Essving et al. 
2009).
Both femoral block and LIA resulted in lo� average pain 
intensity during the first postoperative day. The average degree 
of pain intensity at rest, but not upon movement, �as slightly 
lo�er in the LIA group. This small difference is probably 
�ithout clinical significance. The access to PCA�administered 
morphine until pain �as acceptably lo�, NRS < 4, �ould be 
expected to result in a similar degree of pain relief. The total 
use of morphine per kg �as similar in both groups, �hich 
indicates that the pain relief of both methods �as compara�
ble. Using ancillary analysis, �e found that a pain intensity 
of greater than 7 on NRS �ith movement �as less common 
in the LIA group, a difference that reached statistical signifi�
cance. This result must be regarded as hypothesis generating, 
and should be confirmed by a separate study. 
We compared 2 routinely used methods that are both effec�
tive for postoperative pain relief in TKA. None of the patients 
in this study �ere given an analgesic other than intravenous 
morphine, administered through a PCA pump, and paraceta�
mol (4 g in 24 h).
Femoral block and LIA after TKA have been compared pre�
viously (Parvataneni et al. 2007, Toftdahl et al. 2007). Ho��
ever, in the study by Toftdahl et al., the femoral block group 
also received intraarticular injection of morphine (4 mg) and 
bupivacain (50 mg), and in the study by Parvateneni et al. a 
variable dose of morphine (4–10 mg) and methylprednisolone 
(40 mg) �as given to the LIA group. In both trials, reduced 
opioid consumption �as found �ith LIA. Pain relief at rest 
�as good, but �as similar in the 2 groups during the first 24 h. 
In accordance �ith our findings (�ith fe�er patients reporting 
high�intensity pain on movement in the LIA group), a previ�
ous study has found better pain relief during physiotherapy 
after LIA (Toftdahl et al. 2007). 
The tendency of lo�er efficacy �ith femoral block may be 
due to the fact that the posterior part of the knee is innervated 
by the sciatic nerve. Thus, a femoral block does not cover 
this area and supplementary treatment �ith systemic analge�
sics such as opioids and NSAIDs is needed. In our study, all 
the patients in the femoral group received ketorolac in a total 
dose of 30 mg intravenously during the first 24 h—the same 
amount as administered locally in the LIA group. 
One explanation as to �hy LIA is so effective might be that 
there is evidence for a clinically relevant peripheral analgesic 
action of intraarticular NSAIDs (Romsing et al. 2000). The 
analgesic effect of NSAIDs may be better after intraarticular 
administration than after systemic administration (Day et al. 
1999). Furthermore, in a study comparing the analgesic effect 
of NSAIDs after �ound infiltration �ith that after systemic 
administration, the result �as in favor of local infiltration 
(Ben�David et al. 1995). Our study groups received NSAID 
either intravenously (group F) or via peri� and intraarticular 
infiltration (group LIA), but the study design �as not set up to 
ans�er the question of the most effective route of administra�
tion of NSAID. Furthermore, a clear relationship bet�een the 
dose of NSAIDs and their analgesic effect has been established 
(Collins et al. 1998). Thus, the systemic dose of NSAIDs used 
may have been too lo� for full analgesic effect in the femoral 
group.
The high quality of the femoral blocks in this study might be 
one explanation for the small difference in analgesic efficacy 
bet�een the t�o methods. It is �ell kno�n that the quality of 
a peripheral blockade might depend on the experience of the 
anesthesiologist, and all but 2 blocks �ere performed by an 
experienced anaesthesiologist (FA). 
Experience is also of importance for perioperative local 
infiltration. When �e introduced the LIA method at our insti�
tution, �e noticed that surgeons also have a learning curve 
in doing effective local infiltration. The more experienced the 
surgeon is, the more effective is the postoperative pain relief. 
This may also be due to less tissue trauma being produced by 
experienced surgeons.
Limitations of the study
Open labeled studies have a disadvantage compared to blinded 
studies, due the interference of expectancy of the patient and 
the staff in interpretation of the outcome. The patients in group 
F received an initial femoral nerve block follo�ed by bolus 
doses of ropivacaine every 4 h during the first 24 h, and not 
continuous infusion of local anesthetic, �hich might have been 
more effective due to a steady concentration of ropivacaine 
over time and probably better pain control. The randomization 
procedure �as simple and did not use block design, �hich 
Table 4. Ancillary analysis 
 Femoral block (n = 19) LIA (n = 20)
NRS < 5 at rest 7 12 
NRS < 5 upon movement 5    8 
NRS > 7 at rest 5   1 
NRS > 7 upon movement  7    1 a     
NRS < 5 refers to the number of patients who reported a NRS lower 
than 5 throughout the 24 h of observation. NRS > 7 refers to the 
number of patients who reported pain intensity greater than 7 once 
or more often during the 24 h of observation.
a
 p< 0.05 (Fisher’s exact test).
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could be a disadvantage. Furthermore, stratification according 
to to sex and osteoarthritis or rheumatoid arthritis might have 
resulted in 2 groups �ith less difference.
Since the number of patients �ith rheumatoid arthritis �as 
higher in the LIA group, �e cannot rule out that LIA or femo�
ral block may be more effective in this patient category. The 
observation period of 24 h may be too short, especially �ith 
regard to adverse events. Furthermore, it �ould have been 
good to investigate �hether there �ere differences regarding 
ease of rehabilitation or physical therapy.
 In summary, in this randomized study �e could not confirm 
that there �as any clear superiority of perioperative infiltra�
tion of local anaesthetic (LIA) over femoral block in combi�
nation �ith i.v. ketorolac in total knee arthroplasty, since the 
t�o analgesic regimens gave similar quality of pain treatment 
during the first 24 h. Ho�ever, LIA may be considered the 
preferred option since it is cheaper and easier to perform than 
femoral block. In addition, LIA involves the surgeon in allevi�
ating postoperative pain.
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a b s t r a c t
Pain after total knee arthroplasty (TKA) is difﬁcult to control. A recently developed and increasingly popu-
lar method for postoperative analgesia following knee and hip arthroplasty is Local Inﬁltration Analgesia
(LIA) with ropivacaine, ketorolac and epinephrine. This method is considered to have certain advanta-
ges, which include administration at the site of traumatized tissue, minimal systemic side effects, faster
postoperative mobilization, earlier postoperative discharge from hospital and less opioid consumption.
One limitation, whichmay prevent the widespread use of LIA is the lack of information regarding plasma
concentrations of ropivacaine and ketorolac.
The aimof this academically initiated studywas to detect any toxic or near-toxic plasma concentrations
of ropivacaine and ketorolac following LIA after TKA.
Methods: Forty patients scheduled for primary total knee arthroplasty under spinal anaesthesia, were
randomized to receive either local inﬁltration analgesia with a mixture of ropivacaine 300mg, ketorolac
30mg and epinephrine or repeated femoral nerve block with ropivacaine in combination with three
doses of 10mg intravenous ketorolac according to clinical routine. Plasma concentration of ropivacaine
and ketorolac were quantiﬁed by liquid chromatography–mass spectrometry (LC–MS).
Results: Themaximal detected ropivacaine plasma level in the LIA groupwas not statistically higher than
in the femoral block groupusing theMann–WhitneyU-test (p=0.08).However, themedian concentration
in the LIA group was signiﬁcantly higher than in the femoral block group (p<0.0001; Mann–Whitney
U-test).
The maximal plasma concentrations of ketorolac following administration of 30mg according to the
LIA protocol were detected 1h or 2h after release of the tourniquet in the LIA group: 152–958ng/ml (95%
CI: 303–512ng/ml; n=20). The range of the plasma concentration of ketorolac 2–3h after injection of a
single dose of 10mg was 57–1216ng/ml (95% CI: 162–420ng/ml; n=20).
Conclusion: During the ﬁrst 24h plasma concentration of ropivacaine seems to be lower after repeated
femoral block than after LIA. Since the maximal ropivacaine level following LIA is detected around 4–6h
after release of the tourniquet, cardiac monitoring should cover this interval. Regarding ketorolac, our
preliminary data indicate that the risk for concentration dependent side effects may be highest during
the ﬁrst hours after release of the tourniquet.
Implication: Femoral block may be the preferred method for postoperative analgesia in patients with
increased risk for cardiac side effects from ropivacaine. Administration of a booster dose of ketorolac
shortly after termination of the surgical procedure if LIA was used may result in an increased risk for
toxicity.
© 2011 Scandinavian Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.
DOI of refers to article: 10.1016/j.sjpain.2011.11.003.
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1. Introduction
Pain after TKA is difﬁcult to control. A recently developed and
increasingly popular method for postoperative analgesia following
knee and hip arthroplasty is Local Inﬁltration Analgesia (LIA) with
ropivacaine, ketorolac and epinephrine [1]. This method is consi-
dered to have certain advantages, which include administration
1877-8860/$ – see front matter © 2011 Scandinavian Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.
doi:10.1016/j.sjpain.2011.09.001
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at the site of traumatized tissue, minimal systemic side effects,
faster postoperative mobilization, earlier postoperative discharge
from hospital and less opioid consumption [1–5]. One limitation,
which may prevent the widespread use of LIA is lack of know-
ledge regarding potential toxicity resulting from excessive plasma
concentrations of ropivacaine. Although the manufacturer (Astra-
Zeneca) recommends 300mg ropivacaine as a maximum dose for
inﬁltration, much larger doses are often used [2–6]. Ropivacaine
is a long-acting local anaesthetic agent similar to bupivacaine [7].
It is considered to be less toxic to the central nervous system and
the cardiovascular system [7,8]. The risk of cardiac arrhythmia is
shared with all local anaesthetics and depends on the plasma con-
centration. Signs of toxicity may be observed at 1500ng/ml [7].
Intra-articular doses of 150mg ropivacaine in the knee joint result
inamaximal total plasmaconcentrationof1175ng/ml [9]. The typi-
cal dose of ropivacaine in LIA is 300mg administered over 30min.
Thus, the plasma concentration of ropivacaine following LIA may
reach the threshold for neural and cardiovascular toxicity.
Maximum tolerated doses of local anaesthetics in combination
with epinephrine administered by inﬁltration have not yet been
established [10].
Ketorolac is a non-selective cyclooxygenase inhibitor, which
has been used for postoperative analgesia during almost twenty
years [11]. Local administration affords similar or better pain relief
than systemic administration [12]. However, especially postopera-
tively, there is a dose- and plasma-concentration-dependent risk
of renal side effects with decreased glomerular ﬁltration in addi-
tion to an increased risk of peptic ulcer and bleeding. The peak
plasma concentration of ropivacaine and ketorolac following intra-
and peri-articular inﬁltration is presumably reached later than that
following i.v. administration. However, extensive surgical trauma
and soft-tissue dissectionmay increase systemic absorption during
major orthopedic surgery. This effect may be delayed by the use of
a thigh tourniquet during surgery [13].
The aim of the present randomized, single-site clinical trial was
to collect data on the plasma concentration of ropivacaine and
ketorolac during two different routine protocols of post operative
pain relief in patients scheduled for primary knee arthroplasty in
order to detect any toxic or near-toxic plasma concentrations. One
group (LIA) received intra- and peri-articular injection of ropiva-
caine, ketorolac and epinephrine and the other a femoral block
with ropivacaine and i.v. injection of ketorolac according to clinical
routine.
2. Patients and methods
The present academically initiated randomized trial was con-
ducted in accordancewith theHelsinki Declaration II and approved
by the Regional Research Ethics Committee at the Karolinska Ins-
titutet in Stockholm (2006/397-31/4) and by the Swedish Medical
Products Agency. The enrolment period started in December 2006
and lasted until February 2008.
Inclusion criteria: Adult patients (older than 18 years) with
osteoarthritis or rheumatoid arthritis scheduled for primary uni-
lateral elective total knee arthroplasty, American Society of
Anesthesiologists (ASA) classiﬁcation I–III.
Exclusion criteria: Allergy or intolerance to one of the study
drugs, renal insufﬁciency, epilepsy, language difﬁculty, mental ill-
ness, dementia, QT-interval on Electro Cardio Graph (ECG) >450ms
before start.
After oral and written informed consent, 40 patients scheduled
for primary unilateral total knee arthroplasty under spinal anaest-
hesia were randomly assigned into two groups of postoperative
pain management immediately prior to the surgical procedure:
Femoral block (Group F) received ropivacaine (Narop®, Astra-
Zeneca) av i.v. ketorolac (Toradol®, Roche) at the PACU and
group LIA received peri- and intraarticular inﬁltration with ropiva-
caine +ketorolac (Toradol®, Roche) and epinephrine (Adrenalin®,
NM Pharma).
2.1. Randomization
The randomization sequence was determined by mixing 40
tickets, 20 labelled “F” and 20 labelled “LIA” in sealed opaque enve-
lopes and drawing one envelop at a time. The envelopes were
consecutively numbered from 1 to 40 (Christina Olofsson and Eva-
Britt Nygårds). Information of the procedure for postoperative pain
relief for the ﬁrst patient was found in envelop 1 and for the second
patient in envelop 2 and so on.
2.2. Procedure
Antithrombotic therapy with low molecular weight heparin,
enoxaparinnatrium (Klexane®, Aventis Pharma) 40mg started 12h
before spinal anaesthesia and was given for at least 5 days. Before
induction of spinal anaesthesia monitoring of oxygen saturation,
blood pressure and electrocardiogram (ECG) was started. Sedation
was induced with midazolam (Midazolam®, Alpharma) 1–2mg i.v.
or propofol (Propofol®, Abbot). Puncture for spinal anaesthesiawas
at level L2–3 or L3–4. Isobaric bupivacaine (Marcain Spinal®, Astra-
Zeneca) 5mg/ml at a volume of 3ml was injected with the patient
lying with the operating side upwards. All patients had a urinary
bladder catheter, inserted after spinal anaesthesia and removed the
day after surgery. All patients received 2g dicloxacillin i.v. before
surgery.
The TKA-procedurewas performed following inﬂation of a thigh
tourniquet, which was inﬂated just before skin incision and relea-
sed after wound closure. The release of the tourniquet is time zero
“0” in the LIA group.
Group F received a femoral nerve block directly after spinal
anaesthesia.
Patients were placed in the supine position. Under sterile con-
dition, the pulse of the femoral artery was identiﬁed, the needle
(Plexolong Nanolin cannula facette 19G×50mm®, Pajunk) con-
nected to a nerve stimulator (Simplex B®, Braun: serial no. 17002)
set up to deliver 1.2mA was inserted cephalad 45 angle to skin
at the level of femoral crease 1–1.5 cm lateral to the femoral artery
pulse [14]. The femoral nervewas identiﬁed by eliciting quadriceps
muscle contractions (“dancing patella”). The current was gradually
reduced to achieve twitches of thequadricepsmuscle at 0.2–0.4mA
and the catheter (StimuLong Sono®, Pajunk)was advanced through
the needle.
The connection of the nerve stimulator was changed from
needle to catheter and stimulation intensity was started at 1.2mA
until the desired motor response was obtained. Thereafter, the
intensity was reduced to 0.2–0.4mA. The catheter was secured in
place with transparent dressing (Tegaderm®, 3M). After negative
blood aspiration 30ml ropivacaine 2mg/ml (Narop) was injected
followed by 15ml ropivacaine 2mg/ml 4 hourly for 24h (total
dose ropivacaine 240mg/24h). Group F received ketorolac (Tora-
dol) 10mg intravenously in the Post Anaesthetic Care Unit (PACU),
and again after 8h and 16h. The total dose of ropivacaine during
24h was 240mg and the total dose of ketorolac was 30mg.
Group LIA received peri- and intra-articular inﬁltration with
a mixture of 150ml ropivacaine (2mg/ml), 1ml ketorolac
(30mg/ml), and 5ml epinephrine (0.1mg/ml) (total volume
156ml). This solution was prepared by the operation nurse prior
to the start of the surgical procedure. The solution was given
sequentially; 30mlwas injected intracutaneously at the start of the
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operation, 80mlwas injected into the posterior part of the capsule,
close to the incision line, in the vastus intermedius and lateralis
and around the collateral ligaments before cementation, and 46ml
was instilled through an intraarticular catheter (epidural catheter
gauge 16) inserted at the end of the surgical procedure. The total
dose of ropivacaine during the ﬁrst postoperative 24h was 300mg
and the total dose of ketorolac was 30mg.
In the recovery room all patients were provided with a patient
controlled analgesia (PCA)morphinepump(Abbott PainManager®,
Abbott Laboratories) programmed to give an intravenous bolus
of morphine 2mg/dose on demand with a lock-out time of 6min
and maximum dose of 35mg/4h. All patients were introduced to
the PCA-technique and encouraged to use it as often as needed.
After 24h PCA pump use was veriﬁed by a print out of all doses
of morphine and their time of administration. In addition to PCA
all patients received paracetamol (1 g×4), either orally (Alvedon®,
Astra Zeneca) or i.v. (Perfalgan®, Bristol-Myer Squibb).
Electro Cardio Graph (ECG) was performed preoperatively, 2h
after the end of surgery in the recovery room and 24h postopera-
tively in the ward.
All patients received postoperative physiotherapy, which star-
ted the morning after operation.
2.3. Blood samples
Blood samples for ropivacaine and ketorolac plasma concentra-
tion were drawn from a vein in the arm not used for i.v. infusions,
or from a radial-artery cannula used for patient monitoring. Blood
sampling was started 20min after injecting ropivacaine in the
femoral catheter in group F (Time zero “0” in femoral group). In
the LIA group the release of the tourniquet was time zero “0”. The
ﬁrst sample was taken at 20min. Additional samples were taken at
40 and 60min and 2, 4, 6, 12, 24h. The 12-h samples were taken
only in four patients due to the inconvenient sampling time. The
Table 1
Patient demographics.
Femoral block LIA
Sex (M/F)a 8/11 11/9
Age mean (range) 69 (53–88) 67 (29–85)
Weight (kg) 83±13 78±18
Height (cm) 168±9 171±11
BMI 27 27
ASA I/II/III 2/8/9 3/7/10
RA/OAb 3/16 6/14
Values are expressed as mean (range) or mean± SD.
a M: male, F: female.
b RA: rheumatoid arthritis, OA: osteoarthritis.
blood samples were centrifuged directly, plasma-separated and
immediately frozen and stored at −20 ◦C until assayed.
2.4. Quantiﬁcation of ropivacaine and ketorolac
The reference materials ropivacaine and the internal standard
bupivacaine were obtained from AstraZeneca, Södertälje, Sweden.
The reference material ketorolac trometamol was obtained from
USP, Rockville,MD, USA and the internal standard ketobemidon-d4
was a gift from Prof. Ulf Bondesson (Swedish University of Agricul-
tural Sciences, Uppsala, Sweden).
Ropivacaine was quantiﬁed by LC–MS using Agilent 1100 MSD
(Agilent Technologies, CA, USA). Ketorolac was quantiﬁed by
LC–MS/MSconsistingof aWatersAcquityUPLC (Ultra-performance
liquid chromatograph) connected to a Quattro Premier XE tan-
dem mass spectrometer. The limit of quantiﬁcation was 10ng/ml
for each compound and the maximal calibrated range was
10,000ng/ml. Analytical details are provided by the corresponding
author upon request.
Fig. 1. Consort ﬂow chart.
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Fig. 2. Maximal detected concentration of ropivacaine during 24h. Data expres-
sed as maximal concentration for each patient. The line indicates the median. No
statistical difference was detected between the LIA and femoral block group.
2.5. Statistical analysis
The sample size of this study was based on the power for detec-
tion of a signiﬁcant difference in pain intensity published as a
separate article [15]. A sample size of 20 in each group has an 80%
power to detect a difference between means of 1.0 with a signi-
ﬁcance level (˛) of 0.05 (two-tailed) using the unpaired Student’s
t-test.
The aim of the study was to determine if the plasma con-
centration of ropivacaine and ketorolac after LIA reaches toxic or
near-toxic levels. Thus, mainly descriptive statistics with focus on
maximal plasma concentration are presented. The maximal con-
centration of ropivacaine of each patient in the LIA group was
compared to the maximal concentration of each patient in the
femoral block group by unpaired t-test.
Graphpad Prizm 5.02 for Windows www.graphpad.com was
used for statistical analysis and the graphs.
3. Results
The demographic characteristics were similar in both groups
(Table 1). Plasma concentration of ropivacaine and ketorolac from
one patient in the femoral group was excluded from the study
since levobupivacaine was injected instead of ropivacaine due to
a misunderstanding. Data on the ketorolac concentration of one
patient in the LIA group is not available (Fig. 1).
Table 2
Maximal ropivacaine plasma concentration during 24h [ng/ml].
Range Mean (95% CI)
LIA, n=20 435–1735 813 (644–982)
Femoral block, n=19 122–1151 567 (450–684)
Fig. 4. Total plasma concentration of ketorolac in the LIA group. The LIA group
received 30mg ketorolac. In this group zero “0” refers to release of the tourniquet.
Similar maximal plasma concentrations of ropivacaine were
detected in the LIA group and in the femoral block group during
the ﬁrst 24h (Fig. 2, Table 2). Maximal plasma concentrations in
the LIA group were detected at 4 or 6h after injection (Fig. 3A). In
the femoral block group, the highest levels were often detected at
24h (Fig. 3B).
Themaximal detected ropivacaine plasma level in the LIA group
was not statistically higher than in the femoral block group using
Mann–Whitney U-test (p=0.08). However, the median concentra-
tion in the LIA group (95% CI: 376–611ng/ml) was signiﬁcantly
higher than in the femoral block group (95% CI: 124–183ng/ml)
(<0.0001; Mann–Whitney U-test).
Figure 3. Total plasma concentration of ropivacaine during 24h. (A) LIA group (n=20). In this group zero “0” refers to release of the tourniquet. The LIA group received
300mg ropivacaine. (B) Femoral block group (n=19). In this group time zero “0” refers to completion of the ﬁrst injection for femoral block (60mg), the following doses
(30mg every 4h) are indicated in the ﬁgure.
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The range of the maximal plasma concentrations of ketorolac
1h or 2h after release of the tourniquet in the LIA group was
152–958ng/ml (95% CI: 303–512ng/ml; n=20) (Fig. 4). The femo-
ral block group received three doses of i.v. ketorolac 10mg. Due to
the fact that the i.v. injection of ketorolac at the PACU was per-
formed at different time points depending on the arrival of the
patient,we cannot present a proper concentration curve for ketoro-
lac. The range of the plasma concentration of ketorolac 2–3h after
injection of a single dose of 10mg was 57–1216ng/ml (95% CI:
162–420ng/ml; n=20). At 24h, 2–3h after injection of the third
dose of ketorolac 10mg the range of the plasma concentration was
10–529ng/ml (95% CI: 145–285ng/ml).
4. Discussion
Themaximal plasma concentration of ropivacaine using the LIA
protocol seems to be higher than after femoral block.
Plasma levels of ropivacaine following peri-and intraarticular
injection according to the LIA protocol may approach toxic levels
during theﬁrst 4–6h.However, sincewedidnot analyze theplasma
concentration between 6 and 12, and 12 and 24h, we cannot
exclude the possibility that some individuals displayed maximal
levels later than 6h after induction of LIA. This delayed peak was
not expected and despite insufﬁcient data on the exact time of
maximal plasma concentration from the present study, it may be
wise to consider cardiac monitoring for at least 6h after surgery—a
timepoint when most patients are transferred to ordinary wards
without routine cardiac monitoring.
The plasma concentration of ropivacaine after repeated femoral
blockwas higher than expected and in contrast to a common belief,
the ropivacaine plasma level tended to accumulate during the ﬁrst
24postoperativehoursusing thepresentprotocol. Since theplasma
level of ropivacaine after femoral block had not started to decline at
24h we cannot exclude the possibility of higher ropivacaine levels
after 24h.
The range ofmaximal plasma levels following LIA and following
repeated femoral block displayed a considerable overlap. However,
approximately one-third of the LIA group displayed ropivacaine
levels higher than 1g/ml, as compared to only one individual
following repeated femoral block.
Despite the ﬁnding of higher plasma concentrations of ropi-
vacaine following LIA, we got no indication of adverse cardiac or
CNS events. ECGmonitoring two hours after ending the inﬁltration
of local anaesthetic showed no arrhythmic effect of ropivacaine.
Unfortunately we did not monitor the ECG around 4–6h after LIA
during the highest detected ropivacaine levels. Central nervous and
cardiovascular ropivacaine toxicity has been detected in healthy
volunteers at plasma concentrations of 1–2g/ml following intra-
venous infusion [7,8]. However, studies on peripheral and central
blocks have reported higher plasma concentrations (2–4.2g/ml)
without adverse reactions [16,17]. The ropivacaine concentrations
observed in the present study were below the established toxic
threshold formost of our patients although a few reached a plasma
concentration of 1.4–1.7g/ml.
We are aware of a growing popularity of bolus doses or con-
tinuous infusions to top up preoperative wound inﬁltration of
local anaesthetic after total knee arthroplasty [1,2,18,19]. Since the
maximum concentration of ropivacaine was reached around four
to six hours after giving the total dose, adding a bolus dose of
local anaesthetic early in the postoperative period may result in
potentially hazardous concentrations.
Periarticular administration of 30mg ketorolac according to the
LIA procedure seems to lead to a plasma concentration similar to
that three hours following either a single intravenous injection of
10mg or three hours after three injections of 10mg separated by
8h. Thus, our data may indicate that both routes result in similar
exposure toketorolacor at least similarmaximal levels of ketorolac.
However, since the data points are sparse our present study cannot
determine whether higher plasma levels of ketorolac are reached
with local inﬁltration anaesthesia or with repeated intravenous
administration.
Ourdata indicate that the commonclinical routineof addingoral
or intravenous NSAIDs a few hours after terminating the surgical
procedure if LIA was used may increase the risk of concentration-
dependent side effects of ketorolac.
4.1. Study limitations
One obvious limitation of the present study is that the data
collected on the plasma concentration of ropivacaine and ketoro-
lac following administrationwith LIAdidnot cover thepeakplasma
concentration inmost patients, and the data are insufﬁcient to per-
mit proper pharmacokinetic analysis. Thus our data are hypothesis
generating rather than hypothesis testing. Unfortunately we did
not analyze the free concentration of ropivacaine, nor plasma 1-
acid glycoprotein. The latter is increased after surgery and binds to
ropivacaine and bupivacaine [19] and may prevent the rise of the
free and pharmacologically active fraction of the local anaesthetic.
These aspects are the focus of ongoing studies.
Plasma concentrations of ketorolac appeared to be similar
regardless of route of administration.
However, the plasma samples were not optimized to cover
peak concentration after repeated intravenous administration in
the femoral block group.
Unselective cyclooxygenase inhibitors (NSAIDs) may decrease
renal function and inhibit platelet function and cannot be used for
all patients [20]. In the present study we did not detect increa-
sed bleeding or decreased renal function using routine clinical
monitoring. Thus we cannot exclude a minor increase of posto-
perative bleeding. However, a previous study also in patients with
TKA has assessed the risk for postoperative bleeding with ketoro-
lac [21]. Four intravenous doses of ketorolac 30mg every 6h (total
120mg/24h) did not result in a marked increase of postoperative
bleeding monitored as decreased hematocrite.
Possible renal side effects of ketorolac have been assessed in
healthy, well hydrated patients anaesthetized with sevoﬂurane.
Neither renal glomerular nor tubular dysfunction was detected
[22]. However, elderly patients are at greater risk for renal side
effects and inorder to address this issue indepth, a randomised trial
with a control group not treated with unselective COX-inhibitors
would be needed.
The present experimental protocol using different dosing inter-
vals and doses was not designed to determine whether ketorolac
carries a higher risk for adverse effects after peripheral administra-
tion or after intravenous administration.
The LIA technique has been shown to result in a long lasting pain
relief and reduced need for opioid analgesics [1,2,23]. The average
pain intensity in the LIA group and the femoral block group was
around 2 on a VAS scale in both groups, details are presented in a
separate publication [15].
The direct analgesic effect in the surgical ﬁeld and the addition
of epinephrine, which prolongs the action of the local anaesthetic
agent are obvious reasons. Our ﬁndings also raise the possibility of
a prolonged action due to considerable systemic concentrations of
the local anaesthetic 24h after the administration of ropivacaine.
During the past thirty years preclinical and clinical studies have
reported analgesic effects of intravenously administered sodium
channel blockers. It is still unclear whether intravenously admi-
nistered sodium channel blockers can affect acute postoperative
pain. Conﬂicting results after perioperative intravenous infusion
of lidocaine have been presented [24–26]. Lidocaine is the most
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commonly used local anaesthetic for intravenous infusion in cli-
nical studies, due to its lower cardio toxicity compared with
long-acting sodium channel blockers. It has a brief effect and most
trials terminate the infusion shortly after the end of the operation,
which prevents accumulation. Ropivacaine has a similar mecha-
nism of action as lidocaine and it seems reasonable to assume that
also ropivacaine may have systemic effects as well. We are not
aware of the use of lidocaine in LIA after total knee or hip arth-
roplasty.
We did not investigate the effect of compression bandage [13]
on thedistributionof ropivacaineandketorolac and it ishard topre-
dict how compression of the lower limb would affect the systemic
distribution of ropivacaine and ketorolac. A lower blood ﬂow may
slow down the time to reach concentration equilibrium between
the leg and the systemic circulation. However, a lower volume of
the leg may increase the systemic concentration slightly.
5. Conclusion
The risk for concentration dependent side effects of ropiva-
caine may be higher after local administration according to the
LIA protocol than using repeated femoral block. Since the maxi-
mal ropivacaine level following LIA is detected around 4–6h after
release of the tourniquet, cardiac monitoring should during this
period be considered. Regarding ketorolac, our preliminary data
indicate that the risk for concentration dependent side effects may
be highest during the ﬁrst hours after release of the tourniquet.
The common routine of administration of a booster dose of keto-
rolac shortly after termination of the surgical procedure, if LIA was
used, may result in an increased risk for toxicity. Our data do not
indicate that local administration of ketorolac is a safer alternative
than repeated intravenous injection and similar restrictions should
be applied for both routes.
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Abstract   
 
This study determined the plasma concentration of ropivacaine by liquid chromatography-
mass spectrometry (LC-MS) during 30 h following Local Infiltration Analgesia (LIA) in 15 
patients with elective hip arthroplasty. The 95 % upper prediction bound of maximal unbound 
plasma concentration or ropivacaine was 0.032 mg/L. Alpha 1 acid glycoprotein did not 
correlate to the fraction of unbound ropivacaine during the first 24 h after LIA. No signs or 
symptoms of systemic local anesthetic toxicity were observed. The Clopper Pearson 95 % 
upper confidence limit for adverse signs was 0.218. 
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Introduction 
Local infiltration analgesia (LIA) with ropivacaine, ketorolac and epinephrine is a technically 
simple  method for postoperative pain management after knee and hip replacement (1), which 
has gained popularity in many countries (7). LIA not only improves postoperative pain, but 
reduces the need for opioid analgesic drugs, and leads to faster rehabilitation and earlier 
discharge from hospital (2-6). Information regarding the pharmacokinetics and safety margin 
of ropivacaine and area under the curve (AUC) after LIA is still sparse. Ropivacaine binds 
mainly to  alpha1-acid glycoprotein (AAG) (8), a plasma protein, which increases upon 
trauma (8-14).  
Local anesthetic toxicity has been reported with doses considered to be safe and without 
proven intravascular placement (15). Large surgical incisions and soft-tissue dissection, 
typical of major orthopedic surgery may lead to peak plasma levels of local anesthetics (16) 
with increased risk for central nervous system and cardiovascular toxicity (17).  
The aim of this study was to determine the maximal plasma concentration of unbound 
ropivacaine during 30 hours following elective primary total hip arthroplasty using LIA for 
postoperative analgesia. In addition, we assessed whether the level of AAG during the first 
postoperative day after LIA correlates to the fraction of unbound ropivacaine.   
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Materials and Methods 
 
This study, conducted between 2010 and 2011, was approved by the IRB and the medical 
product agency of Sweden. We included adult patients, ASA I-III, without allergy to any one 
of the study drugs, creatinine plasma concentration < 100 mmol/L, QT-interval < 450 msec.  
Access to research staff limited inclusion of patients. No eligible patient refused participation.  
All patients had spinal anesthesia at L2-L3 or L3-L4 with isobaric bupivacaine (Marcain 
Spinal®, AstraZeneca). LIA consisted of peri- and intra-articular infiltration with a mixture of 
100 ml ropivacaine (2 mg/ml; Narop®, AstraZeneca), 1 ml ketorolac (30 mg/ml; Toradol®, 
Roche), and 5 ml epinephrine (0,1mg/ml; Adrenalin®, NM Pharma): 20 ml were injected 
subcutaneously at the start of the operation and the remaining 86 ml in the capsula, the 
resutured short outward rotators and the gluteus maximus.  
Quantification of total and unbound ropivacaine 
Sampling started 10 minutes after completing LIA at 10, 20, 30, 45 minutes and 1h, 2h, 3h, 
4h, 6h, 8h, 12 h, 24h and 30h respectively. LC-MS (Agilent 1100 MSD; Agilent 
Technologies, CA) was used. Limits of quantification: 0.0053 mg/L- 2.66 mg/L. Internal 
standard: Doxepine (Sigma-Aldrich, St.Louis, MD). The unbound ropivacaine concentration 
was determined following centrifugation at 5500 g for 10 min at 37 ºC using an Amicon 
ULTRA centrifugal filter.  
Quantification of AAG 
Plasma AAG, collected prior to moving the patient to the operating room and 1h, 4h, 12h and 
24 h post-surgery, was analyzed with nephelometry (Immage by Beckman Coulter). 
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Objective  
The primary aim of this pilot study was to document the maximal plasma concentration and 
the area under the curve (AUC) of unbound ropivacaine during 30 hours after LIA.  
ECG-changes and neurological symptoms of local anesthetic toxicity were monitored 
according to clinical routine.  
Statistics 
This pilot study without prior power calculation used a sample size of 15, based on previous 
experience (18). Prizm 6.0 software (Graphpad Software, San Diego, California) was used to 
calculate AUC. The upper prediction bound for maximal unbound ropivacaine was 2.22 SD  
based on normal distribution. Since zero adverse events were observed, we calculated the 
Clopper Pearson exact value (McCracken CE and Looney SW, "A comparison of methods for 
finding the upper confidence limit for a binomial proportion when zero successes are 
observed," JSM 2011.). Statistica 12, Statsoft OK, was used to calculate linear correlation and 
estimate the statistical power.  P < 0.05 and a power of at least 80 % were required to draw 
any conclusion on correlation.  
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Results 
 
No patient dropped out.  Demographic data and individual results are presented in table 1, 
pharmacokinetic profile for ropivacaine in Fig. 1, AAG profile over time in Fig 2 and 
percentage unbound ropivacaine versus AAG in Fig 3 respectively. The 95 % upper 
prediction bound for unbound ropivacaine was 0.032 mg/L. The statistical power of the linear 
correlation of Cmax versus age or creatinine clearance was 53% and 50% respectively.    
Neither tachycardia, nor arrhythmias on ECG, nor neurological signs of local anesthetic 
toxicity (circumoral paresthesia, tinnitus, muscle twitch or seizure) were detected. The 
Clopper-Pearson 95 % upper confidence limit for adverse signs was 0.218. 
Two hours after surgery no prolongation of QT-interval >450 msec was observed in any 
patient.  
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Discussion 
 
The 95 % upper prediction bound for maximal unbound plasma concentration after injection 
of 200 mg ropivacaine in LIA was 0.032 mg/L. This level is comparable to levels observed 
after LIA without epinephrine (19), and half as high as after 400 mg (20). Plasma 
concentrations within the same range (21-26), or considerably higher (27,28), without adverse 
reactions have been reported during epidural infusion or peripheral nerve block with 
ropivacaine. Side-effects sufficient to stop an intravenous infusion were reported at arterial 
concentrations of 0.34-0.85 mg/L (33).  This range has been considered to represent a relevant 
safety limit in studies reporting the venous plasma concentration of unbound ropivacaine (25, 
28). Using a two-sided test based on our data at least 29 individuals are needed to get a power 
of 80 % to test the hypotheses that the maximal unbound ropivacaine concentration correlates 
with age and creatinine clearance. 
Ropivacaine binds mainly to AAG (12,14) , but previous studies on ropivacaine after LIA 
(16,20,30) do not report the plasma level of AAG. We detected AAG levels similar to those in 
young healthy adults (31). After 24 hours AAG had increased by less than 40 percent. 
However, we did not find any correlation between the plasma concentration of AAG and the 
percentage of unbound plasma concentration of ropivacaine during the first 24 h after LIA 
infiltration. AAG levels may double around 4 days postoperatively and seem to reach a 
maximal concentration at the sixth to twelfth postoperative day (11, 13). An increase of AAG, 
sufficient to decrease the unbound concentration of ropivacaine has been observed later than 
24 hours after surgical trauma (8,21,27,32). An obvious limitation of this hypothesis-
generating pilot study was the small size. Not only the unbound plasma concentration, but 
also physiological, anatomical and pharmacokinetic factors contribute to toxicity of LA (29). 
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Inclusion of more elderly patients with decreased renal function is needed to determine cutoff 
levels for decreased doses of ropivacaine in LIA required for safety concerns.  
 
Conclusions 
Since the unbound ropivacaine concentration after 200 mg of ropivacaine administered during 
LIA is below plasma concentrations linked to adverse cardiac or neurological reactions we 
continue with the same dose of ropivacaine in patients similar to those included in this study. 
AAG levels are of minor importance for unbound ropivacaine plasma concentration during 
the first 24 h after THA with LIA.  Larger studies are needed to test the hypothesis that the 
unbound ropivacaine concentration correlates with age and creatinine clearance.  
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Table 1. Patient demographics and results  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CC: Creatinine clearance was calculated according to Cockroft Gould  
AUC: Area under the curve, M: male, F: female  
 
 
 
 
 
  
15 M II 65 95 24 159 0.012 0.448 - 4 
Patient 
number 
sex 
ASA Age 
years 
Weight 
kg 
BMI 
kg x m2 
CC 
mL/min 
Cmax  
Unbound 
mg/L 
 
Cmax 
Total  
mg/L 
AUC 
unbound 
(0-30h) 
h x mg /L  
Tmax  
Unbound 
hours 
1 M I 65 89 29 82 0.016 0.578 - 4 
2 F I 58 63 24 106 0.013 0.769 0.180 2 
3 M II 54 90 28 134 0.022 0.672 0.317 4 
4 M II 85 75 27 58 0.018 0.995 0.229 4 
5 F I 32 62 24 143 0.015 0.443 0.268 8 
6 F I 35 74 26 150 0.005 0.505 0.075 1 
7 F III 75 100 32 75 0.018 0.872 0.328 12 
8 M III 61 105 36 140 0.023 0.877 0.316 6 
9 M III 79 90 28 62 0.018 1.356 0.290 4 
10 M II 72 83 25 108 0.021 0.754 0.327 4 
11 F III 76 106 40 69 0.026 0.686 0.272 8 
12 F III 71 107 35 98 0.018 0.576 0.313 6 
13 F III 58 106 38 101 0.016 0.548 0.320 6 
14 M III 70 71 24 66 0.031 1.333 0.335 6 
15 M II 65 95 24 159 0.012 0.448 - 4 
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Figure 1. Individual data of unbound [A] and total (bound and unbound) [B] plasma 
concentrations versus time during 30 hours after LIA. The lower limit of the maximal 
tolerated arterial concentration of ropivacaine at the end of an infusion of 10 mg/min in 
healthy volunteers is 0.34 mg/L (33).      
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Figure 2.  Individual plasma concentrations of α-1 acid glycoprotein versus time profile (24 
h) in 14 patients. Time zero “0” indicates a baseline sample prior to surgery. 
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Figure 3.Unbound fraction of ropivacaine at different concentrations of AAG (α-1 acid 
glycoprotein) at 1 h after surgery (open circle), at 4 h after surgery (filled circle), at 12 h 
(open triangle) and 24 h (filled triangle) in 14 patients. 
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Abstract 
 
Background:  Local Infiltration Analgesia (LIA) with local anaesthetic (ropivacaine), a non-
steroidal anti-inflammatory drug (Ketorolac), and epinephrine after lower extremity 
arthroplasty has gained increasing popularity during the last decade. This method has certain 
advantages, which include minimal systemic side effects, faster postoperative mobilization, 
earlier postoperative discharge from hospital and less opioid consumption. However, 
information regarding plasma concentrations of ketorolac after LIA mixture is insufficient to 
predict the risk of renal impairment in patients subjected to arthroplasty. 
Aim: To determine the maximal plasma concentration and the exposure of ketorolac during 
the first 30 h following LIA in hip arthroplasty. 
Methods:  Thirteen patients scheduled for primary total hip arthroplasty with LIA 
(ropivacaine 200 mg, ketorolac 30 mg and epinephrine 0.5 mg in a volume of 106 ml) were 
included. Plasma concentration of ketorolac was quantified by liquid chromatography- mass 
spectrometry (LC-MS). In addition we assessed the effect of increasing age and decreasing 
glomerular filtration rate on the maximal plasma concentration and the total exposure to 
ketorolac during 30 h.  
 Results: The range of the maximal plasma concentration 0.3 – 2.2 mg/L, was detected 30 
minutes – 4 hours after completing the infiltration. Similar plasma levels have been reported 
after intramuscular injection of the same dose of ketorolac to healthy elderly volunteers.  
Conclusion: Exposure to ketorolac after LIA may be comparable to an intramuscular 
injection of the same dose. Decision of dose reduction should be based on clinical assessment 
of risk factors. 
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Introduction 
 
Ketorolac tromethamine is a non-specific cyclooxygenase inhibitor (nonsteroidal anti-
inflammatory drug; NSAID) of the pyrrolizine carboxylic acid class, with analgesic, anti-
inflammatory, and antipyretic properties
1-3
.  Ketorolac decreases acute musculoskeletal and 
post-surgical pain 
4
 and reduces postoperative opioid consumption
5-7
.  
Ketorolac in combination with ropivacaine and epinephrine is used for Local infiltration 
analgesia (LIA) in total knee and hip arthroplasty. This method for postoperative pain 
management has gained popularity in recent years, due to reduced need for opioid analgesic 
drugs, faster rehabilitation and earlier discharge from hospital
8-12
.  However, the important 
role of  NSAID in LIA has been disputed
13
.  
Ketorolac as other NSAIDs /cyclooxygenase inhibitors carry a well-known risk for acute and 
chronic renal impairment
14-16
. Increasing age and decreasing glomerular filtration rate as well 
as treatment with diuretics, angiotensin converting enzyme inhibitors or angiotensin II-
receptor blocking agents have been identified as risk factors for renal impairment
17
.  
The objective of this clinical trial was to determine the maximal plasma concentration and the 
total exposure to ketorolac after local injection of 30 mg ketorolac according to the LIA 
protocol in total hip arthroplasty. In addition we determined if increasing age and decreasing 
GFR may lead to increased plasma levels of ketorolac.  
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Method 
 
The present single-center, open trial was conducted at the Karolinska University Hospital in 
Solna, Sweden in accordance with the Helsinki Declaration II. It was approved by the 
Regional Research Ethics Committee at the Karolinska Institutet in Stockholm (2008/1370-
31) and by the Swedish Medical Products Agency (EudraCT nr 2008-005471-10 protocol 
number 4745).  Oral and written informed consent was obtained. The enrolment period was 
from June 2010 to June 2011. Limited access to research staff affected the speed of inclusion.  
Inclusion criteria: Adult patients (older than 18 years), American Society of 
Anaesthesiologists (ASA) classification I-III, with osteoarthritis or rheumatoid arthritis 
scheduled for primary, unilateral, elective total hip arthroplasty.  
Exclusion criteria: Allergy or intolerance to one of the study drugs, renal insufficiency 
(creatinine clearance < 50 ml/min), epilepsy,  unable to understand the Swedish patient 
information  and informed consent document, mental illness, dementia, QT-interval on 
electrocardiograph (ECG) > 450 msec before start.  
 
Interventions 
All patients had spinal anesthesia at L2-L3 or L3-L4 according to clinical routine with 
isobaric bupivacaine (Marcain Spinal®, AstraZeneca) 5mg/ml at a volume of 3 ml injected 
with the patient lying with the operating side upwards. Sedation was induced with midazolam 
(Midazolam®, Alpharma) 1-2 mg i.v. or propofol (Propofol®, Abbot). Antithrombotic 
prophylaxis with low-molecular-weight heparin, dalteparin natrium (Fragmin®,Pfizer) 
5000IU was started 12 hours before spinal anesthesia and was given for at least 5 days. All 
patients received 2 g dicloxacillin i.v before surgery. Before induction of spinal anesthesia, 
monitoring of oxygen saturation, blood pressure and electrocardiogram (ECG) was started 
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according to clinical routine. In addition, ECG (12-lead) was recorded in all patients 
preoperatively, and 2 h post-surgery in the recovery room. 
 
Local infiltration analgesia (LIA) 
All patients received peri-articular infiltration with a mixture of 100 ml ropivacaine (2 mg/ml; 
Narop®, AstraZeneca), 1 ml ketorolac (30 mg/ml; Toradol®, Roche), and 5 ml epinephrine 
(0,1mg/ml; Adrenalin®, NM Pharma). The total volume was 106 ml. This solution was 
prepared before the surgical procedure started. The solution was given sequentially: 20 ml 
subcutaneously at the start of the operation and the remaining 86 ml in the capsula, the 
resutured short outward rotators and the gluteus maximus.  
 
Blood sampling 
Blood samples for ketorolac plasma concentration (5ml) were collected from a vein in the arm 
not used for i.v. infusions.  Blood sampling was started 10 minutes after completing LIA at 
10, 20, 30, 45 minutes and 1h, 2h, 3h, 4h, 6h, 8h, 12 h, 24h and 30h respectively. The blood  
samples were centrifuged directly, plasma-separated, immediately frozen and stored at -20
o
 C 
until assayed. Blood samples for serum albumin and creatinine were collected preoperatively. 
 
Quantification  
Ketorolac was quantified by LC-MS/MS (Waters Acquity Ultra-performance liquid 
chromatograph with a vacuum degasser, binary pump, and sample manager connected to a 
Quattro Premier XE tandem mass spectrometer with MassLynx™/Target Lynx™ Software 
version 4.1 (Waters Co, Milford, MA, USA). The reference material ketorolac trometamol 
was obtained from USP, Rockville, MD, USA and the internal standard ketobemidon-d4 was 
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a gift from Prof. Ulf Bondesson (Swedish University of Agricultural Sciences, Uppsala, 
Sweden). The limit of quantification was 0.01 mg/L for each compound and the calibrated 
range was up to 10 mg/L. Methodological details can be provided upon request.  
 
Aim 
 
The primary aim of this study was to determine the maximal plasma concentration as well as 
the area under the curve (AUC) of ketorolac during 30 h after LIA.  
The secondary aim was to analyze if the patient age, creatinine clearance, weight, or body 
mass index (BMI) correlated to the maximal concentration or AUC of ketorolac.   
 
 
Pharmacokinetic and Statistical Analysis 
 
For this pilot study without power calculation a sample size of 13 was regarded as sufficient 
based on previous experience
18
. Descriptive statistics was used. Statistical analysis including 
correlation (Pearson) and the AUC were performed with Prizm 6.0 software (Graphpad 
Software, San Diego, California). Significance was defined as p< 0.05. 
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Results 
 
A total of 13 patients were enrolled in the study. These patients were operated by the same 
surgeon (P.W.) duration time of surgery was 1.12-1.25 h. The range of serum albumin was 
33-44 g/L.  Patient demographics are presented in Table 1. 
The median of the peak (maximal detected concentration) ketorolac plasma concentrations 
was 0.82 mg/L (range: 0.31-2.16 mg/L).  The 95 % confidence interval was: 0.51-1.13 mg/L.  
One patient (No 2) displayed a peak concentration and AUC almost twice as high compared 
to the other patients. Individual data on the maximal detected ketorolac concentration and the 
total exposure to ketorolac expressed as AUC are shown in Table 1.  The 95 % confidence 
interval for age, creatinine clearance, weight and BMI were 58-74 years, 77-115 ml/min, 80-
98 kg and 27-34 kg/m
2
 respectively.  
The pharmacokinetic profiles for ketorolac concentrations during the 30 post-operative hours 
are shown in Fig. 1. Neither age, nor creatinine clearance, nor patient weight nor BMI 
displayed a significant correlation to the peak ketorolac concentration (Fig 2.) or to the AUC 
(Fig 3). 
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Discussion  
 
To the best of our knowledge this is the first study to investigate ketorolac plasma 
concentration and pharmacokinetics after LIA in hip arthroplasty. The range of the maximal 
detected plasma concentration of ketorolac after LIA was 0.31-2.16 mg/L. We had one outlier 
with a maximal concentration twice as high as the other patients (pat # 2). Our range seems to 
overlap with the range reported after intramuscular injection of the same dose (30 mg) to 
healthy elderly volunteers (1.45-3.82 mg/L)
18
.  Time to peak concentration was 30 min to 4 
hours in our patients, who received epinephrine in LIA as compared to 30 min to 2 hours after 
intramuscular injection
18
. We could not find any correlation between peak concentration or 
Cmax and the patient age within our cohort. These results are in line with the results after an 
intramuscular injection of 30 mg ketorolac in young adults (mean age 30 years) and healthy 
elderly (mean age 72 years)
18
.  
 
Decreasing creatinine clearance did not increase the peak concentration of ketorolac within 
the range present in our cohort 58-150 ml/min. Renal function is more important for total 
exposure or AUC than the peak concentration after a single dose. However, we could not find 
any correlation between creatinine clearance and AUC either. In contrast, a tendency towards 
higher AUC after intramuscular injection of 30 mg ketorolac to elderly as compared to 
younger adults has been reported
18
 . We cannot exclude the possibility that individuals with 
creatinine clearance lower than 50 ml/min may have higher AUC. But due to safety concern 
of ketorolac in patients with reduced renal function a clinical trial on this issue may be 
ethically questionable.    
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In patient #2, the peak plasma concentration was at least 70 percent higher and the AUC was 
at least 100 percent higher than all other patients in this study. A possible explanation for this 
outlier could be an undetected partial intravascular injection during infiltration or infiltration 
in proximity to a larger blood vessel in combination with relatively low body weight and 
female sex. 
Neither weight nor BMI had any significant effect on the peak plasma concentration or total 
exposure of ketorolac. Our cohort was rather homogenous, but we could not even detect any 
trend. The volume of distribution of ketorolac is 0.1- 0.3 L/kg
19
. Thus, the amount of total 
body water seems to be more important for the pharmacokinetic profile than body weight.     
 
In summary our study may suggest that the peak concentration of ketorolac and the total 
exposure to ketorolac after LIA shows small inter individual variation within a small patient 
cohort for elective orthopedic surgery. However, these data cannot be used to assess the 
potential risk for adverse events with ketorolac, since other factors than peak plasma level or 
AUC may be more important to predict the risk for renal side effects. A concentration that 
may be safe in one individual may cause renal impairment in another individual. Renal 
prostaglandins do not appear to play a significant role in the maintenance and regulation of 
renal blood flow under normal conditions in healthy individuals. However, in patient with 
decreased renal function and in the presence of risk factors the response of the kidney to 
NSAIDs will be different, since the production of local renal prostaglandins 
20
 is crucial for 
the maintenance of renal function in the face of hemodynamic compromise.   
 
Risk factors that make patients more susceptible to the renal side effects of NSAIDs drugs 
include advanced age, preexisting mild renal dysfunction, volume depletion, congestive heart 
10 
 
failure, cirrhosis and gastrointestinal bleeding 
21
. Combination of NSAIDs and drugs used for 
treatment of hypertension and heart failure (diuretics and angiotensin converting enzyme 
inhibitors ACE-inhibitors) may impair renal function further
17
.  
Acute and chronic impairment of renal function have been reported as complications of 
treatment with NSAIDs. Although toxicity has been associated with repeated use for several 
days, renal failure can occur after a single dose
20-22
. During the last two years our department 
had two cases of renal failure in patients treated with ketorolac in the LIA mixture after hip 
and knee arthroplasty. Both patients were older than 70 years and were on treatment with 
ACE-inhibitors. One patient required dialysis treatment
23
 . 
The focus of this study was quantification of the plasma concentration of ketorolac after LIA. 
Limitations of this study were the lack sufficient previous data that could be used to calculate 
an adequate power.  A control group treated with the same dose of ketorolac as used in LIA, 
but via the intramuscular route would be the ultimate test to determine if the exposure to 
ketorolac is lower or higher using the LIA protocol.  
 
Thus, this study is hypothesis generating rather than hypothesis testing. Our data did not 
indicate a correlation between age, creatinine clearance and body weight or BMI and the 
maximal ketorolac plasma concentration or total exposure to ketorolac (AUC).  Our patient 
cohort could have been too small to detect a correlation. In addition, a patient cohort with a 
wider confidence interval of age, creatinine clearance, weight and BMI should be studied to 
address the issue of correlation.    
No clinical signs of decreased renal function were observed during the course of this study. 
However, minor effects might have escaped detection in clinical routine. In order to test the 
hypothesis if ketorolac in LIA decreases renal function, a more specific marker of glomerular 
11 
 
filtration, such as cystatin C prior to LIA and after LIA should be monitored. Another 
limitation of this study was the determination of total and not unbound concentration of 
ketorolac. However, ketorolac is highly protein bound (more than 99 %) and our patients had 
normal plasma albumin.   
 
Conclusions  
Within our patient cohort of relatively healthy elderly patients with normal renal function 
increasing age and decreasing renal function did not seem to increase exposure to ketorolac.  
Decision of dose reduction should be based on clinical assessment of risk factors. 
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Table 1.  
 
  Patient 
number 
Sex Age 
[years] 
Creatinine 
clearance  
mL/ min 
Weight  
[kg] 
BMI 
kg/m
2
 
AUC    
0-30 h  
[mg x h 
/L] 
Cmax  
[mg/L] 
Tmax 
[hours] 
1 Male 65 82 89 29.4 NA 1.039 4  
2 Female 58 106 63 23.7 22.847 2.167 2  
3 Male 54 134 90 27.8 8.856 1.259 1  
4 Male 85 58 75 26.9 11.212 1.146 2  
5 Female 35 150 74 26.2 4.704 0.358 0.75 
6 Female 75 75 100 32.3 6.740 0.474 3  
7 Male 61 140 105 35.5 5.801 0.571 3  
8 Male 79 62 90 28.4 5.878 0.547 1  
9 Male 72 108 83 24.5 8.747 0.608 2  
10 Female 76 69 106 40.4 7.156 0.675 0.5 
11 Female 71 98 107 34.9 6.058 0.313 4  
12 Female 58 101 106 38.0 10.258 1.016 0.75 
13 Male 70 66 71 23.5 6.600 0.470 4  
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Figure 1. Individual data of total plasma concentration of ketorolac versus time during 30 
hours after LIA (n=13). 
 
  
16 
 
Figure  2 
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Figure 2. Maximum detected concentration (Cmax) of total ketorolac in relation to  
age (A), creatinine clearance (B), body weight (C)  and BMI (D) (n=13). 
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Figure 3 
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Figure 3. Total exposure of ketorolac expressed as area under the curve AUC (0-30h) in 
correlation to patient age (A), creatinine clearance (B), body weight (C) and BMI (D) (n=12). 
 
 
 
 
 
 
 
 
 
